Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Mar. 31, 2019 | Jun. 28, 2019 | Sep. 30, 2018 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | CHINA JO-JO DRUGSTORES, INC. | ||
Entity Central Index Key | 0001413263 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --03-31 | ||
Document Type | 10-K | ||
Document Period End Date | Mar. 31, 2019 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2019 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Ex Transition Period | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 25,500,000 | ||
Entity Common Stock, Shares Outstanding | 32,936,786 | ||
Entity File Number | 001-34711 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
CURRENT ASSETS | ||
Cash | $ 9,322,463 | $ 15,132,640 |
Restricted cash | 15,422,739 | 16,319,551 |
Financial assets available for sale | 180,928 | 175,140 |
Notes receivable | 177,278 | 279,082 |
Trade accounts receivable | 8,692,514 | 8,322,393 |
Inventories | 13,955,202 | 13,429,568 |
Other receivables, net | 4,438,230 | 3,098,079 |
Advances to suppliers | 1,950,252 | 3,447,452 |
Other current assets | 2,063,375 | 2,116,237 |
Total current assets | 56,202,981 | 62,320,142 |
PROPERTY AND EQUIPMENT, net | 8,727,358 | 2,843,640 |
OTHER ASSETS | ||
Long-term investment | 24,243 | 40,890 |
Farmland assets | 825,259 | 796,286 |
Long term deposits | 2,157,275 | 2,501,968 |
Other noncurrent assets | 1,196,197 | 1,253,352 |
Intangible assets, net | 3,597,323 | 4,056,414 |
Total other assets | 7,800,297 | 8,648,910 |
Total assets | 72,730,636 | 73,812,692 |
CURRENT LIABILITIES | ||
Accounts payable, trade | 23,106,230 | 25,259,526 |
Notes payable | 25,951,673 | 19,180,200 |
Other payables | 3,197,221 | 4,272,523 |
Other payables - related parties | 795,179 | 850,342 |
Customer deposits | 771,942 | 4,040,867 |
Taxes payable | 125,859 | 366,040 |
Accrued liabilities | 1,264,182 | 841,993 |
Total current liabilities | 55,212,286 | 54,811,491 |
Financial liability | 465,248 | |
Purchase option and warrants liability | 81,935 | 138,796 |
Total liabilities | 55,759,469 | 54,950,287 |
COMMITMENTS AND CONTINGENCIES | ||
STOCKHOLDERS’ EQUITY | ||
Common stock; $0.001 par value; 250,000,000 shares authorized; 28,936,778 and 28,936,778 shares issued and outstanding as of March 31, 2019 and March 31, 2018 | 28,937 | 28,937 |
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2019 and March 31, 2018 | ||
Additional paid-in capital | 44,905,664 | 43,599,089 |
Statutory reserves | 1,309,109 | 1,309,109 |
Accumulated deficit | (30,587,468) | (29,661,190) |
Accumulated other comprehensive income | 2,508,964 | 3,586,460 |
Total stockholders' equity | 18,165,206 | 18,862,405 |
Noncontrolling interests | (1,194,039) | |
Total equity | 16,971,167 | 18,862,405 |
Total liabilities and stockholders' equity | $ 72,730,636 | $ 73,812,692 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2019 | Mar. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 250,000,000 | 250,000,000 |
Common stock, shares issued | 28,936,778 | 28,936,778 |
Common stock, shares outstanding | 28,936,778 | 28,936,778 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive (Loss) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
REVENUES, NET | $ 107,551,012 | $ 96,112,706 |
COST OF GOODS SOLD | 82,442,969 | 75,987,537 |
GROSS PROFIT | 25,108,043 | 20,125,169 |
SELLING EXPENSES | 24,265,184 | 18,739,492 |
GENERAL AND ADMINISTRATIVE EXPENSES | 1,718,989 | 17,823,661 |
IMPAIRMENT OF LONG-LIVED ASSETS | 1,583,186 | |
TOTAL OPERATING EXPENSES | 25,984,173 | 38,146,339 |
LOSS FROM OPERATIONS | (876,130) | (18,021,170) |
INTEREST INCOME | 112,887 | 478,976 |
OTHER INCOME, NET | (93,311) | 201,096 |
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY | (326,452) | 357,421 |
LOSS BEFORE INCOME TAXES | (1,183,006) | (16,983,677) |
PROVISION FOR INCOME TAXES | 134,763 | 76,256 |
NET LOSS | (1,317,769) | (17,059,933) |
OTHER COMPREHENSIVE LOSS | ||
Foreign currency translation adjustments | (1,077,496) | 2,236,398 |
COMPREHENSIVE LOSS | $ (2,395,265) | $ (14,823,535) |
WEIGHTED AVERAGE NUMBER OF SHARES: | ||
Basic | 28,936,778 | 25,241,748 |
Diluted | 28,936,778 | 25,241,748 |
LOSS PER SHARES: | ||
Basic | $ (0.03) | $ (0.68) |
Diluted | $ (0.03) | $ (0.68) |
Consolidated Statements of Chan
Consolidated Statements of Changes in Equity - USD ($) | Common Stock | Paid-in capital | Retained Earnings Statutory reserves | Retained Earnings Unrestricted | Accumulated other comprehensive income/(loss) | Non-controlling interest | Total |
Balance at Mar. 31, 2017 | $ 25,215 | $ 36,581,248 | $ 1,309,109 | $ (12,601,257) | $ 1,350,062 | $ 26,664,377 | |
Balance, Shares at Mar. 31, 2017 | 25,214,678 | ||||||
Stock based compensation | $ 3,722 | 7,017,841 | 7,021,563 | ||||
Stock based compensation, Shares | 3,722,100 | ||||||
Net loss | (17,059,933) | (17,059,933) | |||||
Foreign currency translation loss | 2,236,398 | 2,236,398 | |||||
Balance at Mar. 31, 2018 | $ 28,937 | 43,599,089 | 1,309,109 | (29,661,190) | 3,586,460 | 18,862,405 | |
Balance, Shares at Mar. 31, 2018 | 28,936,778 | ||||||
Stock based compensation | 197,100 | 197,100 | |||||
Increase in capital of Jiuzhou Pharmacy | 7,529 | 7,529 | |||||
Start-up of Linjia Medical | 223,629 | 223,629 | |||||
Sale of 10% of Jiuxin Medicine | 1,101,946 | (1,027,082) | 74,864 | ||||
Net loss | (926,278) | (391,491) | (1,317,769) | ||||
Foreign currency translation loss | (1,077,496) | 905 | (1,076,591) | ||||
Balance at Mar. 31, 2019 | $ 28,937 | $ 44,905,664 | $ 1,309,109 | $ (30,587,468) | $ 2,508,964 | $ (1,194,039) | $ 16,971,167 |
Balance, Shares at Mar. 31, 2019 | 28,936,778 |
Consolidated Statements of Ch_2
Consolidated Statements of Changes in Equity (Parenthetical) | 12 Months Ended |
Mar. 31, 2019 | |
Statement of Stockholders' Equity [Abstract] | |
Sale of Jiuxin Medicine | 10.00% |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ (1,317,769) | $ (17,059,933) |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Bad debt direct write-off and provision | (3,357,851) | 4,009,636 |
Depreciation and amortization | 1,676,413 | 1,383,810 |
Impairment of leasehold improvement | 1,583,186 | |
Stock based compensation | 197,100 | 7,021,563 |
Change in fair value of purchase option derivative liability | 326,452 | (357,421) |
Change in operating assets: | ||
Accounts receivable, trade | (116,810) | (2,072,486) |
Notes receivable | 83,910 | (1,005) |
Inventories and biological assets | (1,390,823) | (2,411,209) |
Other receivables | (1,308,437) | (489,334) |
Advances to suppliers | 3,612,453 | 1,121,006 |
Long term deposit | 183,841 | 15,103 |
Other current assets | (83,372) | (377,391) |
Other noncurrent assets | (23,511) | 36,091 |
Change in operating liabilities: | ||
Accounts payable, trade | (528,353) | 3,726,625 |
Other payables and accrued liabilities | (328,473) | 1,115,267 |
Customer deposits | (3,011,194) | 1,048,939 |
Taxes payable | (216,792) | (362,513) |
Net cash provided by operating activities | (5,603,216) | (2,070,066) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Disposal of financial assets available for sale | 87,290 | |
Purchase of financial assets available for sale | (104,360) | (75,513) |
Acquisition of equipment and building | (5,450,934) | (414,398) |
Increase intangible assets | (29,817) | (1,140,102) |
Additions to leasehold improvements | (1,828,360) | (1,347,489) |
Net cash provided by (used in) investing activities | (7,326,181) | (2,977,502) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Repayment of short-term bank loan | ||
Change in restricted cash | ||
Proceeds from notes payable | 42,030,521 | 27,461,423 |
Repayment of notes payable | (34,018,811) | (22,476,740) |
Increase in financial liability | 81,997 | |
Proceeds from sale of stock and warrants | 7,529 | |
Repayment of other payables-related parties | (22,655) | (91,395) |
Net cash provided by (used in) financing activities | 8,078,581 | 4,893,288 |
EFFECT OF EXCHANGE RATE ON CASH | (1,856,174) | 3,810,661 |
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (6,706,989) | 3,656,381 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | 31,452,191 | 27,795,810 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | 24,745,202 | 31,452,191 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Cash paid for income taxes | $ 56,422 | $ 27,825 |
Description of Business and Org
Description of Business and Organization | 12 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
DESCRIPTION OF BUSINESS AND ORGANIZATION | Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), was incorporated in Nevada on December 19, 2006, originally under the name "Kerrisdale Mining Corporation". On September 24, 2009, the Company changed its name to "China Jo-Jo Drugstores, Inc." in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. ("Renovation"), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. ("Jiuxin Management"), Zhejiang Shouantang Medical Technology Co., Ltd. ("Shouantang Technology") and Hangzhou Jiutong Medical Technology Co., Ltd ("Jiutong Medical"), Hangzhou Jiuyi Medical Technology Co. Ltd. ("Jiuyi Technology"), its wholly-owned subsidiaries. The Company is an online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China ("China" or the "PRC"). The Company's offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. ("Jiuzhou Pharmacy"), a company that the Company controls through contractual arrangements. On March 31, 2017, Jiuxin Management established a subsidiary, Lin'An Jiuzhou Pharmacy Co., Ltd ("Lin'An Jiuzhou") to operates drugstores in Lin'an City. As of March 31, 2019, Jiuzhou Pharmacy has established the following companies, each of which operates a drugstore in Hangzhou City: Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd ("Jiuben Pharmacy") April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd ("Jiuli Pharmacy") May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd ("Jiuxiang Pharmacy") May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd ("Jiuheng Pharmacy") June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd ("Jiujiu Pharmacy") June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd ("Jiuyi Pharmacy") June 8, 2017 Hangzhou Jiumu Pharmacy Co., Ltd ("Jiumu Pharmacy") July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd ("Jiurui Pharmacy") August 4, 2017 The Company's offline retail business also includes three medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine ("Jiuzhou Clinic") and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. ("Jiuzhou Service"), both of which are also controlled by the Company through contractual arrangements. On December 18, 2013, Jiuzhou Service established, and held 51% of, Hangzhou Shouantang Health Management Co., Ltd. ("Shouantang Health"), a PRC company licensed to sell health care products. Shouantang Health was closed in April 2015. In May 2016, Hangzhou Shouantang Bio-technology Co., Ltd. ("Shouantang Bio") set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd.("Kahamadi Bio"), a joint venture specialized in brand name development for nutritional supplements. In 2018, Jiuzhou Pharmacy invested a total of $741,540 (5,100,000RMB) in and held 51% of Zhejiang Jiuzhou Linjia Medical Investment and Management Co. Ltd ("Linjia Medical"), which is operating two new clinics in Hangzhou as of March 31, 2019. On March 29, 2019, Jiuzhou Pharmacy set up and currently holds 51% of the equity of Zhejiang AyiGe Medical Health Management Co., Ltd.("Ayi Health"), which is intended to provide technical support such as IT and customer support to our health management business in the future. The Company currently conducts its online retail pharmacy business through Jiuzhou Pharmacy, which holds the Company's online pharmacy license. Prior to November 2015, the Company primarily conducted its online retail pharmacy business through Zhejiang Quannuo Internet Technology Co., Ltd. In May 2015, the Company established Zhejiang Jianshun Network Technology Co. Ltd, a joint venture with Shanghai Jianbao Technology Co., Ltd. ("Jianshun Network"), in order to develop its online pharmaceutical sales from large commercial medical insurance companies. However, as the strategic cooperation with Yikatong ceased, Jianshun Network was dissolved. On September 10, 2015, Renovation set up a new entity Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November 2015, the Company sold all of the equity interests of Quannou Technology to six individuals for approximately $17,121 (RMB107,074). After the sale, its technical support function has been transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy. The Company's wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine"), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20, 2018, 10% of Jiuxin Medicine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $79,625 (RMB 507,760). The Company's herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. ("Qianhong Agriculture"), a wholly-owned subsidiary of Jiuxin Management. Due to the complexity of the cultivation business, Qianhong Agriculture has not grown herbs in fiscal 2019. The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise ("WFOE") under PRC law ● Registered capital of $14.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Jiuben Pharmacy ● Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuli Pharmacy ● Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuxiang Pharmacy ● Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuheng Pharmacy ● Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiujiu Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyi Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiumu Pharmacy ● Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiurui Pharmacy ● Established in the PRC on August, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements 49% Lin'An Jiuzhou ● Established in the PRC in March 31, 2017 ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million ● Explore retail pharmacy market in Lin'An City 100% Linjia Medical ● Established in the PRC in September27, 2017 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 20 million ● Operates local clinics VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Ayi Health ● Established in the PRC in March 29, 2019 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 10 million ● Provide technical Support for medial service VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong'an Jin and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company's wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Control and common control are defined under the accounting standards as "an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity." Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company's ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company's derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). The carrying amount of the Financial assets available for sale is recorded at fair value and is determined based on unobservable inputs (Level 3)(SeeNote 3). As of March 31 2019, the fair values of our derivative instruments were carried at fair value (See Note 17). As of March 31 2019, the fair values of our Financial liability were carried at fair value (See Note 18) Active Market Observable Unobservable Total Cash and restricted cash $ 24,745,202 - - 24,745,202 Financial assets available for sale - - 180,928 180,928 Notes payable - 25,951,673 - 25,951,673 Financial liability 81,935 81,935 Warrants liability - 465,248 - 465,248 Total $ 24,745,202 26,416,921 262,863 51,424,986 Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Retail sales price adjustments after sales are rare. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer's location. Any loss caused in a shipment will be reimbursed by the Company's courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer's receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) control of the merchandise is transferred to customers, The Company's revenue is net of value added tax ("VAT") collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. C ertain contract liabilities primarily represent the Company's obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example, membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue. Restricted cash The Company's restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers' debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers' medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company's retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company's online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers' balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off. Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets' estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company's property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company's intangible assets are as follows: Estimated Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets' net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was $1,337,529 leasehold improvements impaired in the year ended March 31, 2019. There were $825,259 farmland assets and $1,196,197 prepayment of lease use rights, impaired in the year ended March 31, 2019(See Notes 9 and 11). Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company follows FASB ASC Topic 740, "Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2019 and 2018. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company's products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. Stock based compensation The Company follows the provisions of FASB ASC 718, "Compensation — Stock Compensation," which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $1,023,461 and $641,328 for the years ended March 31, 2019 and 2018, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company's retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. Foreign currency translation The Company uses the United States dollar ("U.S. dollars" or "USD") for financial reporting purposes. The Company's subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi ("RMB"), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at March 31, 2019 and 2018 were translated at 1 RMB to 0.1490 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for years ended March 31, 2019 and 2018 were at 1 RMB to 0.1491 USD and at 1 RMB to 0.1510 USD, respectively. Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board's insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 79,600) per bank. As of March 31, 2019 and March 31, 2018, the Company had deposits totaling $24,730,736 and $31,433,969 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 79,600) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the fiscal year ended March 31, 2019, two vendors collectively accounted for 40.3% of the Company's total purchases and two suppliers accounted for more than 10% of total advances to suppliers. For the fiscal year ended March 31, 2018, one vendor accounted for 19% of the Company's total purchases and another vendor accounted for more than 10% of total advances to suppliers. For the fiscal year ended March 31, 2019, no customer accounted for more than 10% of the Company's total sales and more than 10% of total accounts receivable. For the fiscal year ended March 31, 2018, no customer accounted for more than 10% of the Company's total sales or more than 10% of total accounts receivable. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of future lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The Company adopted this new accounting guidance on January 1, 2019 on a modified retrospective basis. The adoption of this new guidance resulted in an increase in both assets and liabilities of approximately $15 million as of April 1, 2019. The adoption of this new guidance is not expected to have a material impact on the Company's results of operations or cash flows. In June 2016, the FASB issued ASU 2016-13, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," providing financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. For public business entities that are U.S. Securities and Exchange Commission (SEC) filers, the amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All entities may adopt the amendments in this update earlier as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230):Classification of Certain Cash Receipts and Cash Payments," addressing eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The amendments in this update should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The impact of adoption on its Condensed Consolidated Financial Statements for any period presented is not material. In July 2017, the FASB issued Accounting Standards update ("ASU") No. 2017-11, "Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception". Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. We are currently evaluating the impact of the adoption of ASU 2017-11 on our consolidated financial statements. In January 2017, the FASB issued Accounting Standards update ("ASU") No. 2017-04, "Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment" ("ASU 2017-04"), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-4 has no impact on our consolidated financial statements. Adoption of New Revenue Recognition Standard In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08,"Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)," which amends the principal versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in those areas in the new revenue recognition standard. On April 1, 2018, we adopted the guidance in ASC 606 and all the related amendments an |
Financial Assets Available for
Financial Assets Available for Sale | 12 Months Ended |
Mar. 31, 2019 | |
Financial Assets Available for Sale [Abstract] | |
FINANCIAL ASSETS AVAILABLE FOR SALE | NOTE 3 – FINANCIAL ASSETS AVAILABLE FOR SALE As of March 31, 2019 and March 31, 2018, financial assets available for sale amounted to $180,928 (RMB 1,214,500) and $175,140 (RMB 1,100,000), respectively. In the year ended March 31, 2018, the Company invested a total of $159,915 as a limited partner (LP) in a private equity fund (PE fund), which is intended to invest in retail pharmaceutical business. However, as the PE fund has not been able to use its proceeds, it agreed to refund $85,118 (RMB585,000) as of December 31, 2018 Additionally, the Company has signed an investment agreement with Inter Mongolia Songlu Pharmaceutical Co.("Songlu Pharmaceutical") and invested a total of $87,225 (RMB600,000), which accounts for 0.5% shares of Songlu Pharmaceutical. The Company has also invested a total of $14,538 (RMB100,000) in a mutual fund, which can be liquidated by giving notice. |
Trade Accounts Receivable
Trade Accounts Receivable | 12 Months Ended |
Mar. 31, 2019 | |
Receivables [Abstract] | |
TRADE ACCOUNTS RECEIVABLE | NOTE 4 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: March 31, March 31, Accounts receivable $ 11,939,364 $ 12,883,707 Less: allowance for doubtful accounts (3,246,850 ) (4,561,314 ) Trade accounts receivable, net $ 8,692,514 $ 8,322,393 For the years ended March 31, 2019 and 2018, $146,593 and $203,095 in accounts receivable were directly written off, respectively. As of March 31, 2019 and 2018, no trade accounts receivables were pledged as collateral for borrowings from financial institutions. |
Other Current Assets
Other Current Assets | 12 Months Ended |
Mar. 31, 2019 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
OTHER CURRENT ASSETS | Note 5 – OTHER CURRENT ASSETS Other current assets consisted of the following: March 31, March 31, Prepaid rental expenses (1) $ 1,979,852 $ 1,984,856 Prepaid and other current assets 83,523 131,381 Total $ 2,063,375 $ 2,116,237 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. |
Property and Equipment
Property and Equipment | 12 Months Ended |
Mar. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | Note 6 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: March 31, March 31, Building* $ 6,436,297 $ 1,707,145 Leasehold improvements 8,944,025 7,606,496 Farmland development cost 1,781,627 1,904,151 Office equipment and furniture 5,470,084 5,581,554 Motor vehicles 551,927 456,442 Total 23,183,960 17,255,788 Less: Accumulated depreciation (12,111,409 ) (11,905,893 ) Impairment** (2,345,193 ) (2,506,255 ) Property and equipment, net $ 8,727,358 $ 2,843,640 * The increase in property and equipment from March 31, 2018 to December 31, 2018 is primarily due to the purchase of Yueming shop, a new building which cost $4,842,670 (RMB32,482,394). The new shop is located downtown south Hangzhou and adjacent to a super shopping mall. The Company plans to create a new flagship store. ** The variance of impairment from March 31, 2019 to March 31, 2018 is solely caused by exchange rate variance. Total depreciation expense for property and equipment was $1,221,520 and $1,268,282 for the year ended March 31, 2019 and 2018, respectively. |
Advances to Suppliers
Advances to Suppliers | 12 Months Ended |
Mar. 31, 2019 | |
Advances to Suppliers [Abstract] | |
ADVANCES TO SUPPLIERS | Note 7 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits, with or advances to, outside vendors for future inventory purchases. Most of the Company's suppliers require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest. As of March 31, 2019 and March 31, 2018, advance to suppliers consist of the following: March 31, March 31, Advance to suppliers $ 2,477,226 * $ 6,505,545 * Less: allowance for doubtful accounts (526,974 )* (3,058,092 )* Advance to suppliers, net $ 1,950,252 $ 3,447,452 * In fiscal 2019, in order to use our cash more efficiently, Jiuxin Medicine accelerated the collection of advance to suppliers. Specifically, we focused on the collection of aged accounts of advances to suppliers. As we have collected these amounts, our allowance on doubtful accounts decreased. |
Inventory
Inventory | 12 Months Ended |
Mar. 31, 2019 | |
Inventory Disclosure [Abstract] | |
INVENTORY | Note 8 – INVENTORY Inventory consisted of finished goods, valued at $13,955,202 and $13,429,568 as of March 31, 2019 and March 31, 2018, respectively. The Company constantly monitors its potential obsolete products and is allowed to return products close to their expiration date to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory as of March 31, 2019 and March 31, 2018. |
Farmland Assets
Farmland Assets | 12 Months Ended |
Mar. 31, 2019 | |
Farmland Assets [Abstract] | |
FARMLAND ASSETS | Note 9 – FARMLAND ASSETS Farmland assets consist of ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of March 31, 2019 and March 31, 2018,farmland assets are valued as follows: March 31, March 31, 2019 2018 Farmland assets $ 2,341,537 $ 2,416,839 Less: Impairment* (1,516,278 ) (1,620,554 ) Farmland assets, net $ 825,259 $ 796,286 * As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture’s farmland, including their cultivation cost and land lease amortization expense, is approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees is approximately $796,286. As a result, the Company recorded an agricultural inventory impairment of $1,620,554. There are no leasehold impairment expense in fiscal 2019. |
Long Term Deposits, Landlords
Long Term Deposits, Landlords | 12 Months Ended |
Mar. 31, 2019 | |
Long Term Deposits, Landlords [Abstract] | |
LONG TERM DEPOSITS, LANDLORDS | Note 10 – LONG TERM DEPOSITS, LANDLORDS As of March 31, 2019 and March 31, 2018, long term deposits amounted to $2,157,275 and $2,501,968, respectively. Long term deposits are sums deposited with, or advanced to, landlords for the purpose of securing retail store leases that the Company does not anticipate applying or being returned within the next twelve months. Most of the Company's landlords require a minimum payment of nine months' rent, paid upfront, plus additional deposits. |
Other Noncurrent Assets
Other Noncurrent Assets | 12 Months Ended |
Mar. 31, 2019 | |
Other Assets, Noncurrent Disclosure [Abstract] | |
OTHER NONCURRENT ASSETS | Note 11 – OTHER NONCURRENT ASSETS Other noncurrent assets consisted of the following: March 31, March 31, Forest land use rights* $ 1,103,235 $ 1,235,253 Others 92,962 18,099 Total $ 1,196,197 $ 1,253,352 * The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. The amortization of the prepayment for the lease of land use right was approximately $28,071 and $28,377 for the years ended March 31, 2019 and 2018, respectively. The Company’s amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: Years ending March 31, Amount 2020 $ 28,071 2021 28,071 2022 28,071 2023 28,071 2024 28,071 Thereafter 929,519 |
Intangible Assets
Intangible Assets | 12 Months Ended |
Mar. 31, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS | Note 12 – INTANGIBLE ASSETS Net intangible assets consisted of the following at: March 31, March 31, License (1) $ 1,909,700 $ 1,967,934 SAP software 676,336 764,104 Land use rights (2) 1,452,718 1,552,622 Total intangible assets 4,038,754 4,284,660 Less: accumulated amortization (441,431 ) (228,246 ) Intangible assets, net $ 3,597,323 $ 4,056,414 Amortization expense of intangibles amounted to $228,046 and $115,528 for the years ended March 31, 2019 and 2018, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time. (2) In July 2013, the Company purchased the land use rights of a plot of land in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future. |
Notes Payable
Notes Payable | 12 Months Ended |
Mar. 31, 2019 | |
Notes Payable [Abstract] | |
NOTES PAYABLE | Note 13 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank ("HUB"), Zhejiang Tailong Commercial Bank ("ZTCB"), Bank of Hangzhou ("BOH"), and China Merchant Bank ("CMB") that provided working capital in the form of the following bank acceptance notes at March 31, 2019 and March 31, 2018: Origination Maturity March 31, March 31, Beneficiary Endorser date date 2019 2018 Jiuzhou Pharmacy(1) HUB 10/10/17 04/10/18 - 2,522,769 Jiuzhou Pharmacy(1) HUB 11/24/17 05/24/18 - 21,972 Jiuzhou Pharmacy(1) HUB 12/05/17 06/05/18 - 377,347 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,194,135 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,443,554 Jiuzhou Pharmacy(1) HUB 02/05/18 08/05/18 - 2,618,500 Jiuzhou Pharmacy(1) HUB 03/05/18 09/05/18 - 3,072,637 Jiuzhou Pharmacy(1) HUB 11/06/17 05/06/18 - 3,553,014 Jiuzhou Pharmacy(1) HUB 12/05/17 06/05/18 - 1,937,683 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,687,711 Jiuxin Medicine(2) CMB 02/02/18 08/02/18 - 71,648 Jiuxin Medicine(2) CMB 02/07/18 08/07/18 - 95,531 Jiuxin Medicine(2) CMB 03/07/18 09/07/18 538,857 Jiuxin Medicine(2) CMB 03/15/18 09/15/18 44,842 Jiuzhou Pharmacy(1) HUB 11/06/18 05/06/19 500,857 - Jiuzhou Pharmacy(1) HUB 12/12/18 06/12/19 2,236,559 - Jiuzhou Pharmacy(1) HUB 12/20/18 06/20/19 1,072,606 - Jiuzhou Pharmacy(1) HUB 12/29/18 06/29/19 5,504,943 - Jiuzhou Pharmacy(1) HUB 02/14/18 08/14/19 2,587,331 - Jiuzhou Pharmacy(1) HUB 03/06/18 09/06/19 6,600,727 - Jiuxin Medicine(1) HUB 10/11/18 04/11/19 4,461,531 - Jiuxin Medicine(1) HUB 11/06/18 05/06/19 2,987,119 - Total $ 25,951,673 $ 19,180,200 (1) As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2019, the Company had $25,951,673 (RMB 174,203,868) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $15,114,740 (RMB 101,459,590) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,446,381 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank. As of March 31, 2019, the Company had a credit line of approximately $13.26 million in the aggregate from HUB. By putting up a three-year deposit of $10.45 million and the restricted cash of $4.67 million deposited in the banks, the total credit line was $28.38 million. As of March 31, 2019, the Company had approximately $25.95 million of bank notes payable and approximately $2.43 million bank credit line was still available for further borrowing. The bank notes are secured by three shops of Jiuzhou Pharmacy and guaranteed by the Company's major shareholders. |
Taxes
Taxes | 12 Months Ended |
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
TAXES | Note 14 – TAXES Income tax The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carry forwards. Deferred tax assets and liabilities are calculated using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Valuation allowances are provided against deferred income tax assets for amounts which are not considered "more likely than not" to be realized. The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC For the years ended March 31, 2019 and 2018, the components of income tax expense consist of the following: For the year ended March 31, 2019 2018 Current: Federal - - State - - Foreign 134,763 76,256 134,763 76,256 Deferred: Federal - - State - - Foreign - - - - Provision for income taxes 134,763 76,256 A reconciliation of the income tax provision at the federal statutory rate and the effective rate is as follows: For the year Ended March 31, 2019 2018 U.S. Statutory rates 21.0 % 21.0 % Foreign income not recognized in the U.S. (21.0 ) (21.0 ) China income taxes 25.0 25.0 Change in valuation allowance (1) (25.0 ) (25.0 ) Non-deductible expenses-permanent difference (2) (11.4 ) (0.4 ) Effective tax rate (11.4 )% (0.4 )% (1) Represents a non-taxable expense reversal due to overall decrease in allowance for accounts receivable and advances to suppliers. (2) The (11.4)% and (0.4)% rate adjustments for the years ended March 31, 2019 and 2018 represent expenses that primarily include stock option expenses and other expenses incurred by the Company that are not deductible for PRC income tax. The components of the Company's net deferred tax assets are as follows: As of As of Allowance 986,665 1,214,946 Long-lived assets impairment 586,298 395,797 Depreciation and Amortization - 345,952 Accrued expense 1,569,683 245,056 Net operating loss carry forward 1,164,735 654,282 Foreign Tax Credit Carryover 195,000 195,000 Total deferred tax assets (liabilities): 4,502,381 3,051,033 Valuation allowance (4,502,381 ) (3,051,033 ) Net deferred tax assets (liabilities) - - The Company regularly assesses the realizability of its deferred tax assets and establishes a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized. We weigh all available positive and negative evidence, including earnings history and results of recent operations, scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies. Assumptions used to forecast future taxable income often require significant judgment. More weight is given to objectively verifiable evidence. In the event we determine that we would not be able to realize all or part of our net deferred tax assets in the future, a valuation allowance will be established against deferred tax assets in the period in which we make such determination. The need to establish a valuation allowance against deferred tax assets may cause greater volatility in our effective tax rate. As of March 31, 2019 and March 31, 2018, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $816,908, which may be available to reduce future years' taxable income. These carry forwards will expire if not utilized by 2032. In addition, the Company carries a Foreign tax credit of $195,000. As of March 31, 2019 and March 31, 2018, the estimated net operating loss carry forwards for Hong Kong income tax purposes amounted to $1,960,933 and $1,882,276, which may be available to reduce future years' taxable income. As of March 31, 2018 and March 31, 2017, the estimated net operating loss carry forwards for China income tax purposes amounted to $ 2,678,523 and $688,622, which may be available to reduce future years' taxable income. These carry forwards will expire if not utilized in the next five years. On December 22, 2017, the U.S. federal government enacted the 2017 Tax Act. The 2017 Tax Act includes a number of changes in existing tax law impacting businesses, including the transition tax, a one-time deemed repatriation of cumulative undistributed foreign earnings and a permanent reduction in the U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. ASC 740 requires companies to recognize the effect of tax law changes in the period of enactment, accordingly, the effects must be recognized on companies' calendar year-end financial statements, even though the effective date for most provisions is January 1, 2018. As a result, we re-measured our net U.S. deferred tax assets at the 21% future tax rate. As of December 31, 2017, for estimating our foreign undistributed earnings according to the 2017 Tax Act, we estimated an aggregate deficit in "accumulated earnings and profits," which is how foreign undistributed earnings are determined for the one-time transition tax and for U.S. income tax purposes. As a result, the one-time transition tax did not have a significant impact on the Company's FY18 tax provision and there was no undistributed accumulated earnings and profits as of March 31, 2019. In December 2017, the SEC issued Staff Accounting Bulletin No. 118 ("SAB 118"), which provided a measurement period of up to one year from the enactment date of the 2017 Tax Act for us to complete the accounting for the 2017 Tax Act and its related impacts. The income tax effects of the 2017 Tax Act for which the accounting is incomplete include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have made reasonable provisional estimates for each of these items, however, these estimates may be affected by other analyses related to the 2017 Tax Act, including but not limited to, any deferred adjustments related to the filing of our fiscal 2019 federal and state income tax returns and further guidance yet to be issued. The Company recorded net unrecognized tax benefits of $0.0 million as of January 31, 2019. It is our policy to classify accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years as the Company's most significant tax jurisdiction. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company's liability for income taxes. Any such adjustment could be material to the Company's results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. |
Postretirement Benefits
Postretirement Benefits | 12 Months Ended |
Mar. 31, 2019 | |
Retirement Benefits [Abstract] | |
POSTRETIREMENT BENEFITS | Note 15 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee's current compensation as required by the local government. The Company contributed $1,423,449 and $1,257,362 in employment benefits and pension for the years ended March 31, 2019 and 2018, respectively. |
Related Party Transactions and
Related Party Transactions and Arrangements | 12 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS | Note 16 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: March 31, March 31, Due to a director and CEO (1) 795,179 850,342 (1) Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. As of March 31, 2019 and March 31, 2018, notes payable totaling $0 and $3,253,630 were secured by the personal properties of certain of the Company's shareholders, respectively. The Company leases a retail space from Mr. Lei Liu. The lease expires in September 2020. Rent expenses totaled $27,605 and $18,120 for the twelve months ended March 31, 2019 and 2018, respectively. The amounts owed under the lease for the twelve months ended December 31, 2019 and 2018 were not paid to Mr. Liu as of March 31, 2019. On April 28, 2018, 10% of Jiuxin Medicine was sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of approximately $75,643 (RMB507,760). Mr. Lei Liu owns 51% of Hangzhou Kangzhou Biotech Co. Ltd. |
Warrants
Warrants | 12 Months Ended |
Mar. 31, 2019 | |
Warrants [Abstract] | |
WARRANTS | Note 17 – WARRANTS In connection with the registered direct offering closed on July 19, 2015, the Company issued to an investor a warrant to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The warrant became exercisable on January 19, 2016 and will expire on January 18, 2021. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 72,000 shares. Such warrant has the same terms as the warrant issued to investor in the offering. The fair value of the warrants issued to purchase 672,000 shares as described above was estimated by using the binominal pricing model with the following assumptions: Common Stock Common Stock March 31, March 31, Stock price $ 2.62 $ 1.35 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 1.80 2.80 Risk-free interest rate 2.27 % 1.98 % Expected volatility 67.69 % 68.73 % (1) As of March 31, 2019, the warrants had not been exercised. Upon evaluation, the warrants meet the definition of a derivative under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the warrants was classified as a liability of $138,796 as of March 31, 2018. For the year ended March 31, 2019, the Company recognized a loss of $326,452 for the investor warrant and placement agent warrant, from the change in fair value of the warrant liability, respectively. As a result, the warrant liability is carried on the consolidated balance sheets at the fair value of $465,248 for the investor warrant and placement agent warrant, collectively, as of March 31, 2019. |
Financial Liability
Financial Liability | 12 Months Ended |
Mar. 31, 2019 | |
Financial Liability [Abstract] | |
Financial Liability | Note 18 – Financial Liability To encourage operating team, which consists of doctors and nurses, to devote their efforts to run clinics, Linjia Medical allows them to put deposits in the clinic where doctors and nurses work, and take shares in any profit of the clinic. The principal amounts of these deposits are refundable in the event the doctors and nurses leave the clinic. In order to properly reflect Linjia Medical's liabilities, the Company reclassified the deposit of $81,935 (RMB550,000) as financial liability as of March 31, 2019. |
Stockholder's Equity
Stockholder's Equity | 12 Months Ended |
Mar. 31, 2019 | |
Stockholders' Equity Note [Abstract] | |
STOCKHOLDER'S EQUITY | Note 19 – STOCKHOLDER’S EQUITY Common stock On January 23, 2017, the Company closed a private offering with one institutional investor (the “Investor”) pursuant to which the Company sold to the Investor, and the Investor purchased from the Company, an aggregate of 4,840,000 shares of the common stock, par value $0.001 per share, of the Company, at a purchase price of $2.20 per share, for aggregate gross proceeds to the Company of $10,648,000 (the “Private Placement”). On April 11,2019, the Company closed a registered direct offering of 4,000,008 shares of common stock at $2.50 per share with gross proceeds of $10,000,020 from an effective shelf registration statement on Form S-3. Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. Share-based awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under FASB ASC 718 “Compensation - Stock Compensation.” The assumptions used in calculating the fair value of share-based payment awards represent the Company’s best estimates. The Company’s estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. On March 30, 2018, the Company granted a total of 3,947,100 shares of restricted common stock to its key employees in its retail drugstores and online pharmacy under the Company’s 2010 Equity Incentive Plan, as amended (the “Plan”). The stock awards vested on the grant date. On June 28, 2018, the compensation committee of the Company canceled 225,000 shares granted to the CEO in order to conform aggregate issuances to the 675,000 share limitation set forth in the Plan. The Tax Cuts and Jobs Act of 2017 removed the 162(m) qualified performance based compensation exemption to the $1 million cap on deductions for compensation to covered executives. Section 1.3.2 was in the Plan to permit grants under the Plan to fit within that exemption. As that exemption no longer applies for grants made in 2018 or thereafter, the Plan has been amended to remove the provisions intended to comply with that exemption, including the one in Section 1.3.2 of the Plan. All $5,328,585 of such expense has been recorded as a service compensation expense in the year ended March 31, 2018. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the years ended March 31, 2019 and 2018, $0 and $313,651 were recorded as compensation expenses. As of March 31, 2019, all compensation costs related to stock option compensation arrangements granted have been recognized. Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the years ended March 31, 2019 and 2018, the Company did not make appropriations to statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so. |
Loss Per Share
Loss Per Share | 12 Months Ended |
Mar. 31, 2019 | |
LOSS PER SHARES: | |
LOSS PER SHARE | Note 20 – LOSS PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted earnings per share computation: The year ended 2019 2018 Net income attributable to controlling interest $ (926,278 ) $ (17,059,933 ) Weighted average shares used in basic computation 28,936,778 25,241,748 Diluted effect of stock options and warrants - Weighted average shares used in diluted computation 28,936,778 25,241,748 Income per share – Basic: Net income before noncontrolling interest $ (0.03 ) $ (0.68 ) Add: Net loss attributable to noncontrolling interest $ - $ - Net income attributable to controlling interest $ (0.03 ) $ (0.68 ) Loss per share – Diluted: Net income before noncontrolling interest $ (0.03 ) $ (0.68 ) Add: Net income attributable to noncontrolling interest $ - $ - Net income attributable to controlling interest $ (0.03 ) $ (0.68 ) For the year ended March 31, 2019, 967,000 shares underlying employee stock options and 600,000 shares underlying outstanding purchase options to an investor, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive. |
Segments
Segments | 12 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
SEGMENTS | Note 21 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter ("OTC") medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy sells OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms such as Alibaba's Tmall, JD.com and Amazon.com, and the Company's own platform all over China. The drug wholesale segment includes supplying the Company's own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company's herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments' accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company's reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2019: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 72,334,409 $ 8,784,459 $ 26,432,144 $ - $ 107,551,012 Cost of goods 51,246,983 7,748,519 23,447,467 - 82,442,969 Gross profit $ 21,087,426 $ 1,035,940 $ 2,984,677 $ - $ 25,108,043 Selling expenses 18,930,118 1,735,966 3,599,100 - 24,265,184 General and administrative expenses 4,072,500 347,516 (2,701,027 ) 1,718,989 * Impairment of long-lived assets - - - Loss from operations $ (1,915,192 ) $ (1,047,542 ) $ 2,086,604 $ $ (876,130 ) Depreciation and amortization $ 1,476,903 $ - $ 7,644 $ - $ 1,484,547 Total capital expenditures $ 7,267,847 $ - $ 1,434 $ - $ 7,269,281 * includes additional accounts receivable and advance to suppliers allowance of $(3,845,582) The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2018: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 61,977,582 $ 12,132,930 $ 22,002,194 $ - $ 96,112,706 Cost of goods 45,918,540 10,858,160 19,210,837 - 75,987,537 Gross profit $ 16,059,042 $ 1,274,770 $ 2,791,357 $ - $ 20,125,169 Selling expenses 13,037,239 2,014,414 3,687,839 - 18,739,492 General and administrative expenses 14,730,152 427,772 2,630,278 35,459 17,823,661 * Impairment of long-lived assets - - 1,583,186 - 1,583,186 Loss from operations $ (11,708,349 ) $ (1,167,416 ) $ (5,109,946 ) $ (35,459 ) $ (18,021,170 ) Depreciation and amortization $ 837,195 $ - $ 377,912 $ - $ 1,215,107 Total capital expenditures $ 878,121 $ - $ 10,915 $ - $ 889,036 * includes additional accounts receivable and advance to suppliers allowance of $4,701,647 The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB's accounting standard, the Company's net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2019 and 2018 were as follows: For the year ended March 31, 2019 2018 Prescription drugs $ 23,516,046 $ 20,553,179 OTC drugs 31,401,328 28,368,059 Nutritional supplements 6,354,108 4,179,139 TCM 6,529,790 1,660,301 Sundry products 941,491 6,254,286 Medical devices 3,591,646 962,619 Total $ 72,334,409 $ 61,977,583 The Company's net revenue from external customers through online pharmacy by main product category is as follows: For the year ended March 31, 2019 2018 Prescription drugs $ - $ OTC drugs 3,127,976 5,193,051 Nutritional supplements 737,315 29,717 TCM 74,262 3,932,607 Sundry products 2,736,070 1,880,707 Medical devices 2,108,836 1,096,849 Total $ 8,784,459 $ 12,132,931 The Company's net revenue from external customers through wholesale by main product category is as follows: For the years ended March 31, 2019 2018 Prescription drugs $ 16,745,862 $ 12,314,829 OTC drugs 8,964,587 9,381,932 Nutritional supplements 290,534 182,903 TCM 271,280 73,645 Sundry products 24,846 48,852 Medical devices 135,035 32 Total $ 26,432,144 $ 22,002,193 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | Note 22 – COMMITMENTS AND CONTINGENCIES Operating lease commitments The Company recognizes lease expenses on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs. The Company's commitments for minimum rental payments under its leases for the next five years and thereafter are as follows: Periods ending March 31, Retail Online Drug Herb Total 2020 $ 4,952,693 $ - $ - $ - $ 4,952,693 2021 4,041,356 - - - 4,041,356 2022 3,236,573 - - - 3,236,573 2023 2,317,018 - - - 2,317,018 2024 1,735,252 - - - 1,735,252 Thereafter 2,039,618 - - - 2,039,618 On March 31, 2018, the Company started outsourcing its logistic service to Astro Boy Cloud Pan (Hangzhou) Storage and Logistic Co. Ltd, Jiuxin Medicine's warehouse lease has been canceled. Instead, Astro Boy Cloud provides both storage and logistic service. Total rent expenses amounted to $4,744,200 and $4,160,748 for the years ended March 31, 2019 and 2018, respectively. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Mar. 31, 2019 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | Note 23 – SUBSEQUENT EVENTS On April 15, 2019, the Company closed a registered direct offering of 4,000,008 shares of common stock at $2.50 per share with gross proceeds of $10,000,020 from its effective shelf registration statement on Form S-3 pursuant to a Securities Purchase Agreement dated April 11, 2019 (the "2019 Securities Purchase Agreement"), by and among the Company and the investors named therein. Concurrently, the Company issued unregistered warrants to the investors in a private placement to purchase up to an aggregate of 3,000,006 shares of common stock at an exercise price of $3.00 per share (the "2019 Warrants"). The 2019 Warrants shall be initially exercisable six months following issuance and expire five and one-half years from the issuance date of the 2019 Warrants. H.C. Wainwright & Co., LLC (the "Placement Agent") (or its designees) shall also receive warrants to purchase such number of shares of common stock as is equal to 6% of the aggregate number of shares of common stock sold in the offering, or 240,000 warrants, with substantially the same terms as the 2019 Warrants being issued to the investors, except that the Placement Agent's warrants will expire on April 11, 2024 and the warrants' exercise price shall be $3.125. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of presentation and consolidation | Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. |
Consolidation of variable interest entities | Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. |
Risks and Uncertainties | Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company's ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. |
Use of estimates | Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. |
Fair value measurements | Fair value measurements The Company establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). The carrying amount of the Financial assets available for sale is recorded at fair value and is determined based on unobservable inputs (Level 3)(SeeNote 3). As of March 31 2019, the fair values of our derivative instruments were carried at fair value (See Note 17). As of March 31 2019, the fair values of our Financial liability were carried at fair value (See Note 18) Active Market Observable Unobservable Total Cash and restricted cash $ 24,745,202 - - 24,745,202 Financial assets available for sale - - 180,928 180,928 Notes payable - 25,951,673 - 25,951,673 Financial liability 81,935 81,935 Warrants liability - 465,248 - 465,248 Total $ 24,745,202 26,416,921 262,863 51,424,986 |
Revenue recognition | Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Retail sales price adjustments after sales are rare. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) control of the merchandise is transferred to customers, The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. C ertain contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example, membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue. |
Restricted cash | Restricted cash The Company's restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. |
Accounts receivable | Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers' debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers' medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company's retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company's online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers' balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. |
Advances to suppliers | Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off. |
Inventories | Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. |
Farmland assets | Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. |
Property and equipment | Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets' estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company's property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. |
Intangible assets | Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company's intangible assets are as follows: Estimated Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. |
Impairment of long lived assets | Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets' net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was $1,337,529 leasehold improvements impaired in the year ended March 31, 2019. There were $825,259 farmland assets and $1,196,197 prepayment of lease use rights, impaired in the year ended March 31, 2019(See Notes 9 and 11). |
Notes payable | Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. |
Income taxes | Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2019 and 2018. |
Value added tax | Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. |
Stock based compensation | Stock based compensation The Company follows the provisions of FASB ASC 718, "Compensation — Stock Compensation," which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. |
Advertising and promotion costs | Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $1,023,461 and $641,328 for the years ended March 31, 2019 and 2018, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. |
Operating leases | Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company's retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. |
Foreign currency translation | Foreign currency translation The Company uses the United States dollar ("U.S. dollars" or "USD") for financial reporting purposes. The Company's subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi ("RMB"), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at March 31, 2019 and 2018 were translated at 1 RMB to 0.1490 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for years ended March 31, 2019 and 2018 were at 1 RMB to 0.1491 USD and at 1 RMB to 0.1510 USD, respectively. |
Concentrations and credit risk | Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board's insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 79,600) per bank. As of March 31, 2019 and March 31, 2018, the Company had deposits totaling $24,730,736 and $31,433,969 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 79,600) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the fiscal year ended March 31, 2019, two vendors collectively accounted for 40.3% of the Company's total purchases and two suppliers accounted for more than 10% of total advances to suppliers. For the fiscal year ended March 31, 2018, one vendor accounted for 19% of the Company's total purchases and another vendor accounted for more than 10% of total advances to suppliers. For the fiscal year ended March 31, 2019, no customer accounted for more than 10% of the Company's total sales and more than 10% of total accounts receivable. For the fiscal year ended March 31, 2018, no customer accounted for more than 10% of the Company's total sales or more than 10% of total accounts receivable. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of future lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The Company adopted this new accounting guidance on January 1, 2019 on a modified retrospective basis. The adoption of this new guidance resulted in an increase in both assets and liabilities of approximately $15 million as of April 1, 2019. The adoption of this new guidance is not expected to have a material impact on the Company’s results of operations or cash flows. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” providing financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. For public business entities that are U.S. Securities and Exchange Commission (SEC) filers, the amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All entities may adopt the amendments in this update earlier as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230):Classification of Certain Cash Receipts and Cash Payments,” addressing eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The amendments in this update should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The impact of adoption on its Condensed Consolidated Financial Statements for any period presented is not material. In July 2017, the FASB issued Accounting Standards update (“ASU”) No. 2017-11, “Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception”. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. We are currently evaluating the impact of the adoption of ASU 2017-11 on our consolidated financial statements. In January 2017, the FASB issued Accounting Standards update (“ASU”) No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-4 has no impact on our consolidated financial statements. |
Adoption of New Revenue Recognition Standard | Adoption of New Revenue Recognition Standard In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08,“Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. On April 1, 2018, we adopted the guidance in ASC 606 and all the related amendments and applied the new revenue standard to all contracts using the modified retrospective method. Based on the new standard our revenue recognition policies related to membership rewards programs will change. But the impact of the new revenue standard was not material and there was no adjustment required to the opening balance of retained earnings. We expect the impact of the adoption of the new revenue standard to be immaterial to our net income on an ongoing basis. The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard: Pharmacy retail sales The physical pharmacies sell prescription drugs, OTC drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products. Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services are minimal compared to pharmacy retail sales, it is included as part of the pharmacy retail sales. Online pharmacy sales The online pharmacy sells various health products except for prescription drugs. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. Historically, sales returns seven days after merchandise receipts have been minimal. Wholesale Jiuxin Medicine purchases medicine in quantity and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) control of the merchandise is transferred to customers The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source in each segment for the year ended March 31, 2019: For the year ended March 31 2019 2018 Retail drugstores Prescription drugs $ 23,516,046 $ 20,553,179 OTC drugs 31,401,328 28,368,059 Nutritional supplements 6,354,108 4,179,139 TCM 6,529,790 1,660,301 Sundry products 941,491 6,254,286 Medical devices 3,591,646 962,619 Total retail revenue $ 72,334,409 $ 61,977,583 Online pharmacy Prescription drugs $ - $ - OTC drugs 3,127,976 5,193,051 Nutritional supplements 737,315 29,717 TCM 74,262 3,932,607 Sundry products 2,736,070 1,880,707 Medical devices 2,108,836 1,096,849 Total online revenue $ 8,784,459 $ 12,132,931 Drug wholesale Prescription drugs $ 16,745,862 $ 12,314,829 OTC drugs 8,964,587 9,381,932 Nutritional supplements 290,534 182,903 TCM 271,280 73,645 Sundry products 24,846 48,852 Medical devices 135,035 32 Total wholesale revenue $ 26,432,144 $ 22,002,193 Total revenue $ 107,551,012 $ 96,112,706 Contract Balances Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The following table provides information about receivables and contract liabilities from contracts with customers: March 31, March 31, Trade receivable(included in accounts receivable, net) $ 8,692,514 $ 8,322,393 Contract liabilities (included in accrued expenses) 1,689,099 4,461,136 Impact of New Revenue Recognition Standard on Financial Statement Line Items The Company adopted ASU 2014-09 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the condensed statement of operation for the year ended March 31, 2019: Impact of Change in Accounting Policy As Reported Balances For the The year Balance Ended without In thousands March 31, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 107,551 (302 ) 107,249 Cost of revenues 82,443 - 82,443 Gross profit 25,108 (302 ) 24,806 SELLING EXPENSES 24,265 302 24,567 GENERAL AND ADMINISTRATIVE EXPENSES 1,719 - 1,719 Operating profit (876 ) - (1,480 ) Income (loss) before income tax provision (1,183 ) - (1,787 ) Income tax provision 135 - 135 Income (loss) from continuing operations (1,318 ) - (1,922 ) Net income (loss) (1,318 ) - (1,922 ) The adoption of ASU 2014-09 has no effect on consolidated balance sheet and statement of cash flow. |
Adoption of Statement of Cash Flows | The adoption of ASU 2014-09 has no effect on consolidated balance sheet and statement of cash flow. Adoption of Statement of Cash Flows In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows, which amends Accounting Standard Codification ("ASC") Topic 230. This ASU requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. The guidance is required to be applied retrospectively. The Company adopted this new accounting guidance. The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheet to total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows: March 31, March 31, 2019 2018 Cash and cash equivalents 9,322,463 15,132,640 Restricted cash 15,422,739 16,319,551 Total cash, cash equivalents and restricted cash in the statement of cash flows 24,745,202 31,452,191 Restricted cash in the condensed consolidated balance sheets primarily represents deposits required by a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. All restricted cash is invested in time deposits and money markets, which are classified within Level 1 of the fair value hierarchy. Restricted cash activity was previously reported in "Change in restricted cash" within financing activities cash flows on the Company's condensed consolidated statement of cash flows. The following is a reconciliation of the effect on the relevant line items on the statement of cash flows for the year ended March 31, 2018 as a result of adopting this new accounting guidance: As Previously As Reported Adjustments Revised Year Ended March 31, 2018 Change in restricted cash (5,664,224 ) 5,664,224 - Net cash provided by financing activities (770,936 ) 5,664,224 4,893,288 Effects of exchange rate on cash 2,586,720 1,223,941 3,810,661 Net decrease in cash, cash equivalents and restricted cash (3,231,784 ) 6,888,165 3,656,381 Cash, cash equivalents, and restricted cash at the beginning of the period 18,364,424 9,431,386 27,795,810 Cash, cash equivalents, and restricted cash at the end of the period 15,132,640 16,319,551 31,452,191 |
Description of Business and O_2
Description of Business and Organization (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of subsidiaries | Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd ("Jiuben Pharmacy") April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd ("Jiuli Pharmacy") May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd ("Jiuxiang Pharmacy") May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd ("Jiuheng Pharmacy") June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd ("Jiujiu Pharmacy") June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd ("Jiuyi Pharmacy") June 8, 2017 Hangzhou Jiumu Pharmacy Co., Ltd ("Jiumu Pharmacy") July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd ("Jiurui Pharmacy") August 4, 2017 |
Schedule of consolidated financial statements activities | Entity Name Background Ownership Renovation â—Ź Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management â—Ź Established in the PRC on October 14, 2008 â—Ź Deemed a wholly foreign owned enterprise ("WFOE") under PRC law â—Ź Registered capital of $14.5 million fully paid 100% Shouantang Technology â—Ź Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million â—Ź Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid â—Ź Deemed a WFOE under PRC law â—Ź Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture â—Ź Established in the PRC on August 10, 2010 by Jiuxin Management â—Ź Registered capital of RMB 10 million fully paid â—Ź Carries out herb farming business 100% Jiuzhou Pharmacy (1) â—Ź Established in the PRC on September 9, 2003 â—Ź Registered capital of RMB 5 million fully paid â—Ź Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) â—Ź Established in the PRC as a general partnership on October 10, 2003 â—Ź Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuzhou Service (1) â—Ź Established in the PRC on November 2, 2005 â—Ź Registered capital of RMB 500,000 fully paid â—Ź Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuxin Medicine â—Ź Established in PRC on December 31, 2003 â—Ź Acquired by Jiuzhou Pharmacy in August 2011 â—Ź Registered capital of RMB 10 million fully paid â—Ź Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiutong Medical â—Ź Established in the PRC on December 20, 2011 by Renovation â—Ź Registered capital of $2.6 million fully paid â—Ź Currently has no operation 100% Jiuben Pharmacy â—Ź Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuli Pharmacy â—Ź Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuxiang Pharmacy â—Ź Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuheng Pharmacy â—Ź Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiujiu Pharmacy â—Ź Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyi Pharmacy â—Ź Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiumu Pharmacy â—Ź Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiurui Pharmacy â—Ź Established in the PRC on August, 2017 by Jiuzhou Pharmacy â—Ź Registered capital of $15,920 fully paid â—Ź Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Shouantang Bio â—Ź Established in the PRC in October, 2014 by Shouantang Technology â—Ź 100% held by Shouantang Technology â—Ź Registered capital of RMB 1,000,000 fully paid â—Ź Sells nutritional supplements under its own brand name 100% Jiuyi Technology â—Ź Established in the PRC on September 10, 2015 â—Ź 100% held by Renovation â—Ź Technical support to online pharmacy 100% Kahamadi Bio â—Ź Established in the PRC in May 2016 â—Ź 49% held by Shouantang Bio â—Ź Registered capital of RMB 10 million â—Ź Develop brand name for nutritional supplements 49% Lin'An Jiuzhou â—Ź Established in the PRC in March 31, 2017 â—Ź 100% held by Jiuxin Management â—Ź Registered capital of RMB 5 million â—Ź Explore retail pharmacy market in Lin'An City 100% Linjia Medical â—Ź Established in the PRC in September27, 2017 â—Ź 51% held by Jiuzhou Pharmacy â—Ź Registered capital of RMB 20 million â—Ź Operates local clinics VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Ayi Health â—Ź Established in the PRC in March 29, 2019 â—Ź 51% held by Jiuzhou Pharmacy â—Ź Registered capital of RMB 10 million â—Ź Provide technical Support for medial service VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong'an Jin and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Schedule of fair values of derivative instruments | Active Market Observable Unobservable Total Cash and restricted cash $ 24,745,202 - - 24,745,202 Financial assets available for sale - - 180,928 180,928 Notes payable - 25,951,673 - 25,951,673 Financial liability 81,935 81,935 Warrants liability - 465,248 - 465,248 Total $ 24,745,202 26,416,921 262,863 51,424,986 |
Schedule of estimated useful lives of property and equipment | Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years |
Schedule of estimated useful lives of intangible assets | Estimated Land use rights 50 years Software 3 years |
Schedule of revenue by major source in each segment | For the year ended March 31 2019 2018 Retail drugstores Prescription drugs $ 23,516,046 $ 20,553,179 OTC drugs 31,401,328 28,368,059 Nutritional supplements 6,354,108 4,179,139 TCM 6,529,790 1,660,301 Sundry products 941,491 6,254,286 Medical devices 3,591,646 962,619 Total retail revenue $ 72,334,409 $ 61,977,583 Online pharmacy Prescription drugs $ - $ - OTC drugs 3,127,976 5,193,051 Nutritional supplements 737,315 29,717 TCM 74,262 3,932,607 Sundry products 2,736,070 1,880,707 Medical devices 2,108,836 1,096,849 Total online revenue $ 8,784,459 $ 12,132,931 Drug wholesale Prescription drugs $ 16,745,862 $ 12,314,829 OTC drugs 8,964,587 9,381,932 Nutritional supplements 290,534 182,903 TCM 271,280 73,645 Sundry products 24,846 48,852 Medical devices 135,035 32 Total wholesale revenue $ 26,432,144 $ 22,002,193 Total revenue $ 107,551,012 $ 96,112,706 |
Schedule of receivables and contract liabilities from contracts with customers | March 31, March 31, Trade receivable(included in accounts receivable, net) $ 8,692,514 $ 8,322,393 Contract liabilities (included in accrued expenses) 1,689,099 4,461,136 |
Schedule of condensed statement of operation | Impact of Change in Accounting Policy As Reported Balances For the The year Balance Ended without In thousands March 31, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 107,551 (302 ) 107,249 Cost of revenues 82,443 - 82,443 Gross profit 25,108 (302 ) 24,806 SELLING EXPENSES 24,265 302 24,567 GENERAL AND ADMINISTRATIVE EXPENSES 1,719 - 1,719 Operating profit (876 ) - (1,480 ) Income (loss) before income tax provision (1,183 ) - (1,787 ) Income tax provision 135 - 135 Income (loss) from continuing operations (1,318 ) - (1,922 ) Net income (loss) (1,318 ) - (1,922 ) |
Schedule of cash equivalents and restricted cash | March 31, March 31, 2019 2018 Cash and cash equivalents 9,322,463 15,132,640 Restricted cash 15,422,739 16,319,551 Total cash, cash equivalents and restricted cash in the statement of cash flows 24,745,202 31,452,191 |
Schedule of reconciliation of line items on the statement of cash flows | As Previously As Reported Adjustments Revised Year Ended March 31, 2018 Change in restricted cash (5,664,224 ) 5,664,224 - Net cash provided by financing activities (770,936 ) 5,664,224 4,893,288 Effects of exchange rate on cash 2,586,720 1,223,941 3,810,661 Net decrease in cash, cash equivalents and restricted cash (3,231,784 ) 6,888,165 3,656,381 Cash, cash equivalents, and restricted cash at the beginning of the period 18,364,424 9,431,386 27,795,810 Cash, cash equivalents, and restricted cash at the end of the period 15,132,640 16,319,551 31,452,191 |
Trade Accounts Receivable (Tabl
Trade Accounts Receivable (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Receivables [Abstract] | |
Schedule of trade accounts receivable | March 31, March 31, Accounts receivable $ 11,939,364 $ 12,883,707 Less: allowance for doubtful accounts (3,246,850 ) (4,561,314 ) Trade accounts receivable, net $ 8,692,514 $ 8,322,393 |
Other Current Assets (Tables)
Other Current Assets (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Schedule of other current assets | March 31, March 31, Prepaid rental expenses (1) $ 1,979,852 $ 1,984,856 Prepaid and other current assets 83,523 131,381 Total $ 2,063,375 $ 2,116,237 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. |
Property and Equipment (Tables)
Property and Equipment (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |
Schedule of property and equipment | March 31, March 31, Building* $ 6,436,297 $ 1,707,145 Leasehold improvements 8,944,025 7,606,496 Farmland development cost 1,781,627 1,904,151 Office equipment and furniture 5,470,084 5,581,554 Motor vehicles 551,927 456,442 Total 23,183,960 17,255,788 Less: Accumulated depreciation (12,111,409 ) (11,905,893 ) Impairment** (2,345,193 ) (2,506,255 ) Property and equipment, net $ 8,727,358 $ 2,843,640 * The increase in property and equipment from March 31, 2018 to December 31, 2018 is primarily due to the purchase of Yueming shop, a new building which cost $4,842,670 (RMB32,482,394). The new shop is located downtown south Hangzhou and adjacent to a super shopping mall. The Company plans to create a new flagship store. ** The variance of impairment from March 31, 2019 to March 31, 2018 is solely caused by exchange rate variance. |
Advances to Suppliers (Tables)
Advances to Suppliers (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Advances to Suppliers [Abstract] | |
Schedule of advance to suppliers | March 31, March 31, Advance to suppliers $ 2,477,226 * $ 6,505,545 * Less: allowance for doubtful accounts (526,974 )* (3,058,092 )* Advance to suppliers, net $ 1,950,252 $ 3,447,452 * In fiscal 2019, in order to use our cash more efficiently, Jiuxin Medicine accelerated the collection of advance to suppliers. Specifically, we focused on the collection of aged accounts of advances to suppliers. As we have collected these amounts, our allowance on doubtful accounts decreased. |
Farmland Assets (Tables)
Farmland Assets (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Farmland Assets [Abstract] | |
Schedule of farmland assets | March 31, March 31, 2019 2018 Farmland assets $ 2,341,537 $ 2,416,839 Less: Impairment* (1,516,278 ) (1,620,554 ) Farmland assets, net $ 825,259 $ 796,286 * As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture’s farmland, including their cultivation cost and land lease amortization expense, is approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees is approximately $796,286. As a result, the Company recorded an agricultural inventory impairment of $1,620,554. There are no leasehold impairment expense in fiscal 2019. |
Other Noncurrent Assets (Tables
Other Noncurrent Assets (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Other Assets, Noncurrent Disclosure [Abstract] | |
Schedule of other noncurrent assets | March 31, March 31, Forest land use rights* $ 1,103,235 $ 1,235,253 Others 92,962 18,099 Total $ 1,196,197 $ 1,253,352 * The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. |
Schedule of amortizations of the prepayment for lease of land use right | Years ending March 31, Amount 2020 $ 28,071 2021 28,071 2022 28,071 2023 28,071 2024 28,071 Thereafter 929,519 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of net intangible assets | March 31, March 31, License (1) $ 1,909,700 $ 1,967,934 SAP software 676,336 764,104 Land use rights (2) 1,452,718 1,552,622 Total intangible assets 4,038,754 4,284,660 Less: accumulated amortization (441,431 ) (228,246 ) Intangible assets, net $ 3,597,323 $ 4,056,414 Amortization expense of intangibles amounted to $228,046 and $115,528 for the years ended March 31, 2019 and 2018, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time. (2) In July 2013, the Company purchased the land use rights of a plot of land in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future. |
Notes Payable (Tables)
Notes Payable (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Notes Payable [Abstract] | |
Schedule of credit facilities with banks | Origination Maturity March 31, March 31, Beneficiary Endorser date date 2019 2018 Jiuzhou Pharmacy(1) HUB 10/10/17 04/10/18 - 2,522,769 Jiuzhou Pharmacy(1) HUB 11/24/17 05/24/18 - 21,972 Jiuzhou Pharmacy(1) HUB 12/05/17 06/05/18 - 377,347 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,194,135 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,443,554 Jiuzhou Pharmacy(1) HUB 02/05/18 08/05/18 - 2,618,500 Jiuzhou Pharmacy(1) HUB 03/05/18 09/05/18 - 3,072,637 Jiuzhou Pharmacy(1) HUB 11/06/17 05/06/18 - 3,553,014 Jiuzhou Pharmacy(1) HUB 12/05/17 06/05/18 - 1,937,683 Jiuzhou Pharmacy(1) HUB 12/29/17 06/29/18 - 1,687,711 Jiuxin Medicine(2) CMB 02/02/18 08/02/18 - 71,648 Jiuxin Medicine(2) CMB 02/07/18 08/07/18 - 95,531 Jiuxin Medicine(2) CMB 03/07/18 09/07/18 538,857 Jiuxin Medicine(2) CMB 03/15/18 09/15/18 44,842 Jiuzhou Pharmacy(1) HUB 11/06/18 05/06/19 500,857 - Jiuzhou Pharmacy(1) HUB 12/12/18 06/12/19 2,236,559 - Jiuzhou Pharmacy(1) HUB 12/20/18 06/20/19 1,072,606 - Jiuzhou Pharmacy(1) HUB 12/29/18 06/29/19 5,504,943 - Jiuzhou Pharmacy(1) HUB 02/14/18 08/14/19 2,587,331 - Jiuzhou Pharmacy(1) HUB 03/06/18 09/06/19 6,600,727 - Jiuxin Medicine(1) HUB 10/11/18 04/11/19 4,461,531 - Jiuxin Medicine(1) HUB 11/06/18 05/06/19 2,987,119 - Total $ 25,951,673 $ 19,180,200 (1) As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2019, the Company had $25,951,673 (RMB 174,203,868) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $15,114,740 (RMB 101,459,590) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,446,381 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank. |
Taxes (Tables)
Taxes (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Schedule of income arising in or derived from tax jurisdiction which each entity domiciled | Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC |
Schedule of components of income tax expense | For the year ended March 31, 2019 2018 Current: Federal - - State - - Foreign 134,763 76,256 134,763 76,256 Deferred: Federal - - State - - Foreign - - - - Provision for income taxes 134,763 76,256 |
Schedule of reconciliation of the income tax provision at federal statutory rate and effective rate | For the year Ended March 31, 2019 2018 U.S. Statutory rates 21.0 % 21.0 % Foreign income not recognized in the U.S. (21.0 ) (21.0 ) China income taxes 25.0 25.0 Change in valuation allowance (1) (25.0 ) (25.0 ) Non-deductible expenses-permanent difference (2) (11.4 ) (0.4 ) Effective tax rate (11.4 )% (0.4 )% (1) Represents a non-taxable expense reversal due to overall decrease in allowance for accounts receivable and advances to suppliers. (2) The (11.4)% and (0.4)% rate adjustments for the years ended March 31, 2019 and 2018 represent expenses that primarily include stock option expenses and other expenses incurred by the Company that are not deductible for PRC income tax. |
Schedule of net deferred tax assets | As of As of Allowance 986,665 1,214,946 Long-lived assets impairment 586,298 395,797 Depreciation and Amortization - 345,952 Accrued expense 1,569,683 245,056 Net operating loss carry forward 1,164,735 654,282 Foreign Tax Credit Carryover 195,000 195,000 Total deferred tax assets (liabilities): 4,502,381 3,051,033 Valuation allowance (4,502,381 ) (3,051,033 ) Net deferred tax assets (liabilities) - - |
Related Party Transactions an_2
Related Party Transactions and Arrangements (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Schedule of amounts payable to related parties | March 31, March 31, Due to a director and CEO (1) 795,179 850,342 (1) Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. |
Warrants (Tables)
Warrants (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Warrants [Abstract] | |
Schedule of estimated fair value of warrants using the binominal pricing model | Common Stock Common Stock March 31, March 31, Stock price $ 2.62 $ 1.35 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 1.80 2.80 Risk-free interest rate 2.27 % 1.98 % Expected volatility 67.69 % 68.73 % (1) As of March 31, 2019, the warrants had not been exercised. |
Loss Per Share (Tables)
Loss Per Share (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
LOSS PER SHARES: | |
Schedule of reconciliation of the basic and diluted (loss) earnings per share | The year ended 2019 2018 Net income attributable to controlling interest $ (926,278 ) $ (17,059,933 ) Weighted average shares used in basic computation 28,936,778 25,241,748 Diluted effect of stock options and warrants - Weighted average shares used in diluted computation 28,936,778 25,241,748 Income per share – Basic: Net income before noncontrolling interest $ (0.03 ) $ (0.68 ) Add: Net loss attributable to noncontrolling interest $ - $ - Net income attributable to controlling interest $ (0.03 ) $ (0.68 ) Loss per share – Diluted: Net income before noncontrolling interest $ (0.03 ) $ (0.68 ) Add: Net income attributable to noncontrolling interest $ - $ - Net income attributable to controlling interest $ (0.03 ) $ (0.68 ) |
Segments (Tables)
Segments (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Summary of segment of the continuing operations | The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2019: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 72,334,409 $ 8,784,459 $ 26,432,144 $ - $ 107,551,012 Cost of goods 51,246,983 7,748,519 23,447,467 - 82,442,969 Gross profit $ 21,087,426 $ 1,035,940 $ 2,984,677 $ - $ 25,108,043 Selling expenses 18,930,118 1,735,966 3,599,100 - 24,265,184 General and administrative expenses 4,072,500 347,516 (2,701,027 ) 1,718,989 * Impairment of long-lived assets - - - Loss from operations $ (1,915,192 ) $ (1,047,542 ) $ 2,086,604 $ $ (876,130 ) Depreciation and amortization $ 1,476,903 $ - $ 7,644 $ - $ 1,484,547 Total capital expenditures $ 7,267,847 $ - $ 1,434 $ - $ 7,269,281 * includes additional accounts receivable and advance to suppliers allowance of $(3,845,582) The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2018: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 61,977,582 $ 12,132,930 $ 22,002,194 $ - $ 96,112,706 Cost of goods 45,918,540 10,858,160 19,210,837 - 75,987,537 Gross profit $ 16,059,042 $ 1,274,770 $ 2,791,357 $ - $ 20,125,169 Selling expenses 13,037,239 2,014,414 3,687,839 - 18,739,492 General and administrative expenses 14,730,152 427,772 2,630,278 35,459 17,823,661 * Impairment of long-lived assets - - 1,583,186 - 1,583,186 Loss from operations $ (11,708,349 ) $ (1,167,416 ) $ (5,109,946 ) $ (35,459 ) $ (18,021,170 ) Depreciation and amortization $ 837,195 $ - $ 377,912 $ - $ 1,215,107 Total capital expenditures $ 878,121 $ - $ 10,915 $ - $ 889,036 * includes additional accounts receivable and advance to suppliers allowance of $4,701,647 |
Summary of net revenue from external customers through its retail drugstores by main products | For the year ended March 31, 2019 2018 Prescription drugs $ 23,516,046 $ 20,553,179 OTC drugs 31,401,328 28,368,059 Nutritional supplements 6,354,108 4,179,139 TCM 6,529,790 1,660,301 Sundry products 941,491 6,254,286 Medical devices 3,591,646 962,619 Total $ 72,334,409 $ 61,977,583 For the year ended March 31, 2019 2018 Prescription drugs $ - $ OTC drugs 3,127,976 5,193,051 Nutritional supplements 737,315 29,717 TCM 74,262 3,932,607 Sundry products 2,736,070 1,880,707 Medical devices 2,108,836 1,096,849 Total $ 8,784,459 $ 12,132,931 For the years ended March 31, 2019 2018 Prescription drugs $ 16,745,862 $ 12,314,829 OTC drugs 8,964,587 9,381,932 Nutritional supplements 290,534 182,903 TCM 271,280 73,645 Sundry products 24,846 48,852 Medical devices 135,035 32 Total $ 26,432,144 $ 22,002,193 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of company's commitments for minimum rental payments | Periods ending September 30, Retail Online Drug Herb Total 2019 $ 4,590,468 $ - $ - $ - $ 4,590,468 2020 3,699,758 - - - 3,699,758 2021 2,799,515 - - - 2,799,515 2022 2,013,152 - - - 2,013,152 2023 1,342,827 - - - 1,342,827 Thereafter 1,762,033 - - - 1,762,033 |
Description of Business and O_3
Description of Business and Organization (Details) | 12 Months Ended |
Mar. 31, 2019 | |
Hangzhou Jiuben Pharmacy Co., Ltd ("Jiuben Pharmacy") [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Apr. 27, 2017 |
Hangzhou Jiuli Pharmacy Co., Ltd ("Jiuli Pharmacy") [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | May 22, 2017 |
Hangzhou Jiuxiang Pharmacy Co., Ltd (“Jiuxiang Pharmacy”) [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | May 26, 2017 |
Hangzhou Jiuheng Pharmacy Co., Ltd (“Jiuheng Pharmacy”) [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Jun. 6, 2017 |
Hangzhou Jiujiu Pharmacy Co., Ltd ("Jiujiu Pharmacy") [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Jun. 8, 2017 |
Hangzhou Jiuyi Pharmacy Co., Ltd (“Jiuyi Pharmacy”) [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Jun. 8, 2017 |
Hangzhou Jiumu Pharmacy Co., Ltd (“Jiumu Pharmacy”) [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Jul. 21, 2017 |
Hangzhou Jiurui Pharmacy Co., Ltd (“Jiurui Pharmacy”) [Member] | |
Variable Interest Entity [Line Items] | |
Date Established | Aug. 4, 2017 |
Description of Business and O_4
Description of Business and Organization (Details 1) | 12 Months Ended | |
Mar. 31, 2019 | ||
Variable Interest Entity [Line Items] | ||
Entity ownership percentage | 100.00% | |
Renovation [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Incorporated in Hong Kong SAR on September 2, 2008 | |
Entity ownership percentage | 100.00% | |
Jiuxin Management [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise ("WFOE") under PRC law Registered capital of $14.5 million fully paid | |
Entity ownership percentage | 100.00% | |
Shouantang Technology [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid Deemed a WFOE under PRC law Invests and finances the working capital of Quannuo Technology | |
Entity ownership percentage | 100.00% | |
Qianhong Agriculture [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business | |
Entity ownership percentage | 100.00% | |
Jiuzhou Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou | [1] |
Entity ownership description | VIE by contractual arrangements | [2] |
Jiuzhou Clinic [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores | [1] |
Entity ownership description | VIE by contractual arrangements | [2] |
Jiuzhou Service [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores | [1] |
Entity ownership description | VIE by contractual arrangements | [2] |
Jiuxin Medicine [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiutong Medical [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation | |
Entity ownership percentage | 100.00% | |
Jiuben Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiuli Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiuxiang Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiuheng Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiujiu Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiuyi Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiumu Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiurui Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on August, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Shouantang Bio [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in October, 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name | |
Entity ownership percentage | 100.00% | |
Jiuyi Technology [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on September 10, 2015 100% held by Renovation Technical support to online pharmacy | |
Entity ownership percentage | 100.00% | |
Kahamadi Bio [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in May 2016 49% held by Shouantang Bio Registered capital of RMB 10 million Develop brand name for nutritional supplements | |
Entity ownership percentage | 49.00% | |
Lin'An Jiuzhou [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in March 31, 2017 100% held by Jiuxin Management Registered capital of RMB 5 million Explore retail pharmacy market in Lin'An City | |
Entity ownership percentage | 100.00% | |
Linjia Medical [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in September 27, 2017 51% held by Jiuzhou Pharmacy Registered capital of RMB 20 million Operates local clinics | |
Entity ownership description | VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy | [2] |
Ayi Health [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in March 29, 2019 51% held by Jiuzhou Pharmacy Registered capital of RMB 10 million Provide technical Support for medial service | |
Entity ownership description | VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy | [2] |
[1] | Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong'an Jin and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. | |
[2] | To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Description of Business and O_5
Description of Business and Organization (Details Textual) | 1 Months Ended | 12 Months Ended | ||||||||||
Sep. 17, 2009shares | Mar. 31, 2019USD ($) | Mar. 31, 2019CNY (ÂĄ) | Mar. 29, 2019 | Dec. 31, 2018USD ($) | Dec. 31, 2018CNY (ÂĄ) | Apr. 20, 2018USD ($) | Apr. 20, 2018CNY (ÂĄ) | May 31, 2016 | Nov. 30, 2015USD ($) | Nov. 30, 2015CNY (ÂĄ) | Dec. 18, 2013 | |
Description of Business and Organization (Textual) | ||||||||||||
Entity Incorporation, Date of Incorporation | Dec. 19, 2006 | |||||||||||
Jiuzhou Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of ownership | 51.00% | 51.00% | 51.00% | |||||||||
Total amount of investment | $ 741,540 | |||||||||||
Jiuzhou Pharmacy [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 5,000,000 | |||||||||||
Total amount of investment | ÂĄ | ÂĄ 5,100,000 | |||||||||||
Linjia Medical [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of ownership | 51.00% | 51.00% | ||||||||||
Linjia Medical [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 20,000,000 | |||||||||||
Renovation [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | |||||||||||
Issuance of equity consideration, shares | shares | 7,900,000 | |||||||||||
Jiuyuan Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 15,920 | |||||||||||
Jiuyi Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | 15,920 | |||||||||||
Jiuxiang Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 15,920 | |||||||||||
Shouantang Bio [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | 100.00% | ||||||||||
Shouantang Bio [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 1,000,000 | |||||||||||
Jiuyi Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | 100.00% | ||||||||||
Jiuzhou Service [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 500,000 | |||||||||||
Percentage of ownership | 51.00% | |||||||||||
Jiuxin Medicine [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | $ 79,625 | |||||||||||
Percentage of ownership | 10.00% | 10.00% | 49.00% | |||||||||
Jiuxin Medicine [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | ÂĄ | ÂĄ 507,760 | |||||||||||
Registered capital paid | ÂĄ | ÂĄ 10,000,000 | |||||||||||
Kahamadi Bio [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 10,000,000 | |||||||||||
Percentage of ownership | 49.00% | 49.00% | ||||||||||
Jiutong Medical [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 2,600,000 | |||||||||||
Percentage of ownership | 100.00% | 100.00% | ||||||||||
Jiuxin Management [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 14,500,000 | |||||||||||
Percentage of ownership | 100.00% | 100.00% | ||||||||||
Qianhong Agriculture [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of ownership | 100.00% | 100.00% | ||||||||||
Qianhong Agriculture [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 10,000,000 | |||||||||||
Shouantang Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 20,000,000 | |||||||||||
Percentage of ownership | 100.00% | 100.00% | ||||||||||
Registered capital requirement reduced | $ 11,000,000 | |||||||||||
Lin'An Jiuzhou [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of ownership | 100.00% | 100.00% | ||||||||||
Lin'An Jiuzhou [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ÂĄ | ÂĄ 5,000,000 | |||||||||||
Jiuben Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 15,920 | |||||||||||
Jiumu Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | 15,920 | |||||||||||
Jiuheng Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | 15,920 | |||||||||||
Jiujiu Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | 15,920 | |||||||||||
Jiuli Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | 15,920 | |||||||||||
Jiurui Pharmacy [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ 15,920 | |||||||||||
Quannuo Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | $ 17,121 | |||||||||||
Quannuo Technology [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | ÂĄ | ÂĄ 107,074 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Summary of fair values of derivative instruments | ||
Cash and restricted cash | $ 24,745,202 | |
Financial assets available for sale | 180,928 | $ 175,140 |
Notes payable | 25,951,673 | |
Financial liability | 81,935 | |
Warrants liability | 465,248 | |
Total | 51,424,986 | |
Active Market for Identical Assets (Level 1) | ||
Summary of fair values of derivative instruments | ||
Cash and restricted cash | 24,745,202 | |
Notes payable | ||
Financial liability | ||
Warrants liability | ||
Total | 24,745,202 | |
Observable Inputs (Level 2) | ||
Summary of fair values of derivative instruments | ||
Cash and restricted cash | ||
Notes payable | 25,951,673 | |
Financial liability | ||
Warrants liability | 465,248 | |
Total | 26,416,921 | |
Unobservable Inputs (Level 3) | ||
Summary of fair values of derivative instruments | ||
Cash and restricted cash | ||
Financial assets available for sale | 180,928 | |
Notes payable | ||
Financial liability | 81,935 | |
Warrants liability | ||
Total | $ 262,863 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details 1) | 12 Months Ended |
Mar. 31, 2019 | |
Buildings [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 35 years |
Minimum [Member] | Leasehold improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Minimum [Member] | Motor vehicles [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Minimum [Member] | Office equipment & furniture [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Maximum [Member] | Leasehold improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 10 years |
Maximum [Member] | Motor vehicles [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 5 years |
Maximum [Member] | Office equipment & furniture [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 5 years |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies (Details 2) | 12 Months Ended |
Mar. 31, 2019 | |
Land use rights [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Estimated useful life of intangible assets | 50 years |
Software [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Estimated useful life of intangible assets | 3 years |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies (Details 3) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 107,551,012 | $ 96,112,706 |
Retail drugstores [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 72,334,409 | 61,977,583 |
Retail drugstores [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 23,516,046 | 20,553,179 |
Retail drugstores [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 31,401,328 | 28,368,059 |
Retail drugstores [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 6,354,108 | 4,179,139 |
Retail drugstores [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 6,529,790 | 1,660,301 |
Retail drugstores [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 941,491 | 6,254,286 |
Retail drugstores [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,591,646 | 962,619 |
Online pharmacy [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 8,784,459 | 12,132,931 |
Online pharmacy [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | ||
Online pharmacy [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,127,976 | 5,193,051 |
Online pharmacy [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 737,315 | 29,717 |
Online pharmacy [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 74,262 | 3,932,607 |
Online pharmacy [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2,736,070 | 1,880,707 |
Online pharmacy [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2,108,836 | 1,096,849 |
Drug wholesale [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 26,432,144 | 22,002,193 |
Drug wholesale [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 16,745,862 | 12,314,829 |
Drug wholesale [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 8,964,587 | 9,381,932 |
Drug wholesale [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 290,534 | 182,903 |
Drug wholesale [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 271,280 | 73,645 |
Drug wholesale [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 24,846 | 48,852 |
Drug wholesale [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 135,035 | $ 32 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies (Details 4) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Accounting Policies [Abstract] | ||
Trade receivable(included in accounts receivable, net) | $ 8,692,514 | $ 8,322,393 |
Contract liabilities (included in accrued expenses) | $ 1,689,099 | $ 4,461,136 |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies (Details 5) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Condensed Consolidated Statement of Operations: | ||
Net revenues | $ 107,551,012 | $ 96,112,706 |
Cost of revenues | 82,442,969 | 75,987,537 |
Gross profit | 25,108,043 | 20,125,169 |
SELLING EXPENSES | 24,265,184 | 18,739,492 |
GENERAL AND ADMINISTRATIVE EXPENSES | 1,718,989 | 17,823,661 |
Operating profit | (876,130) | (18,021,170) |
Income (loss) before income tax provision | (1,183,006) | (16,983,677) |
Income tax provision | 134,763 | 76,256 |
Net income (loss) | (1,317,769) | $ (17,059,933) |
As Reported [Member] | ||
Condensed Consolidated Statement of Operations: | ||
Net revenues | 107,551,000 | |
Cost of revenues | 82,443,000 | |
Gross profit | 25,108,000 | |
SELLING EXPENSES | 24,265,000 | |
GENERAL AND ADMINISTRATIVE EXPENSES | 1,719,000 | |
Operating profit | (876,000) | |
Income (loss) before income tax provision | (1,183,000) | |
Income tax provision | 135,000 | |
Income (loss) from continuing operations | (1,318,000) | |
Net income (loss) | (1,318,000) | |
Adjustments [Member] | ||
Condensed Consolidated Statement of Operations: | ||
Net revenues | (302,000) | |
Cost of revenues | ||
Gross profit | (302,000) | |
SELLING EXPENSES | 302,000 | |
GENERAL AND ADMINISTRATIVE EXPENSES | ||
Operating profit | ||
Income (loss) before income tax provision | ||
Income tax provision | ||
Income (loss) from continuing operations | ||
Net income (loss) | ||
Balance without Adoption of Topic 606 [Member] | ||
Condensed Consolidated Statement of Operations: | ||
Net revenues | 107,249,000 | |
Cost of revenues | 82,443,000 | |
Gross profit | 24,806,000 | |
SELLING EXPENSES | 24,567,000 | |
GENERAL AND ADMINISTRATIVE EXPENSES | 1,719,000 | |
Operating profit | (1,480,000) | |
Income (loss) before income tax provision | (1,787,000) | |
Income tax provision | 135,000 | |
Income (loss) from continuing operations | (1,922,000) | |
Net income (loss) | $ (1,922,000) |
Summary of Significant Accou_10
Summary of Significant Accounting Policies (Details 6) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | Mar. 31, 2017 |
Accounting Policies [Abstract] | |||
Cash and cash equivalents | $ 9,322,463 | $ 15,132,640 | |
Restricted cash | 15,422,739 | 16,319,551 | |
Total cash, cash equivalents and restricted cash in the statement of cash flows | $ 24,745,202 | $ 31,452,191 | $ 27,795,810 |
Summary of Significant Accou_11
Summary of Significant Accounting Policies (Details 7) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Change in restricted cash | ||
Net cash provided by financing activities | 8,078,581 | 4,893,288 |
Effects of exchange rate on cash | (1,856,174) | 3,810,661 |
Net decrease in cash, cash equivalents and restricted cash | (6,706,989) | 3,656,381 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | 31,452,191 | 27,795,810 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | 24,745,202 | 31,452,191 |
As Previously Reported [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Change in restricted cash | (5,664,224) | |
Net cash provided by financing activities | (770,936) | |
Effects of exchange rate on cash | 2,586,720 | |
Net decrease in cash, cash equivalents and restricted cash | (3,231,784) | |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | 15,132,640 | 18,364,424 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | 15,132,640 | |
Adjustments [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Change in restricted cash | 5,664,224 | |
Net cash provided by financing activities | 5,664,224 | |
Effects of exchange rate on cash | 1,223,941 | |
Net decrease in cash, cash equivalents and restricted cash | 6,888,165 | |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | $ 16,319,551 | 9,431,386 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | $ 16,319,551 |
Summary of Significant Accou_12
Summary of Significant Accounting Policies (Details Textual) | 12 Months Ended | ||
Mar. 31, 2019USD ($)VendorsSupplier | Mar. 31, 2018USD ($)Vendors | Mar. 31, 2015USD ($) | |
Summary of Significant Accounting Policies (Textual) | |||
Voting ownership interest | 50.00% | ||
Ownership percentage | 100.00% | ||
Value added tax, percentage | 17.00% | ||
Advertising and promotion costs | $ 1,023,461 | $ 641,328 | |
Term of agreement for operating leases | 30 years | ||
Foreign currency translation, description | The balance sheet amounts, with the exception of equity, at March 31, 2019 and 2018 were translated at 1 RMB to 0.1490 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for years ended March 31, 2019 and 2018 were at 1 RMB to 0.1491 USD and at 1 RMB to 0.1510USD, respectively. | ||
Insurance covered by own bank | $ 79,600 | ||
Bank uncovered amount | 79,600 | ||
Deposits | $ 24,730,736 | 31,433,969 | |
Impairment of assets | 1,583,186 | ||
Farmland assets | 825,259 | $ 796,286 | |
Leasehold improvements | 1,337,529 | ||
Increase in both assets and liabilities | 15,000,000 | ||
Prepayment of lease use rights | $ 1,196,197 | ||
Wholesale Warehouse [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Term of agreement for operating leases | 10 years | ||
Minimum [Member] | Retail [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Term of agreement for operating leases | 3 years | ||
Maximum [Member] | Retail [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Term of agreement for operating leases | 10 years | ||
Total purchases [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Concentration risk, percentage | 40.30% | 19.00% | |
Number of vendors | Vendors | 2 | 1 | |
Total advances to suppliers [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Concentration risk, percentage | 10.00% | 10.00% | |
Number of supplier | Supplier | 2 | ||
Sales Revenue, Net [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Concentration risk, percentage | 10.00% | 10.00% | |
Accounts Receivable [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Concentration risk, percentage | 10.00% | 10.00% | |
RMB [Member] | |||
Summary of Significant Accounting Policies (Textual) | |||
Insurance covered by own bank | 500,000 | ||
Bank uncovered amount | $ 500,000 |
Financial Assets Available fo_2
Financial Assets Available for Sale (Details) | Mar. 31, 2019USD ($) | Mar. 31, 2019CNY (ÂĄ) | Dec. 31, 2018USD ($) | Dec. 31, 2018CNY (ÂĄ) | Apr. 20, 2018 | Mar. 31, 2018USD ($) | Mar. 31, 2018CNY (ÂĄ) | May 31, 2016 | Dec. 18, 2013 |
Financial Assets Available for Sale (Textual) | |||||||||
Financial assets available for sale | $ | $ 180,928 | $ 175,140 | |||||||
Investment agreement fund | $ | $ 85,118 | ||||||||
Invested total amount | $ | $ 14,538 | $ 159,915 | |||||||
Kahamadi Bio [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 49.00% | 49.00% | |||||||
Zhejiang Shouantang Medical Technology [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 100.00% | 100.00% | |||||||
Hangzhou Qianhong Agriculture Development [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 100.00% | 100.00% | |||||||
Zhejiang Jiuxin Investment Management [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 100.00% | 100.00% | |||||||
Hangzhou Jiutong Medical Technology [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 100.00% | 100.00% | |||||||
Zhejiang Jiuxin Medicine [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 10.00% | 49.00% | |||||||
Hangzhou Jiuzhou Medical and Public Health Service [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Percentage of shares | 51.00% | ||||||||
Songlu Pharmaceutical [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Invested total amount | $ | $ 87,225 | ||||||||
Percentage of shares | 0.50% | 0.50% | |||||||
RMB [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Financial assets available for sale | ÂĄ | ÂĄ 1,214,500 | ÂĄ 1,100,000 | |||||||
Investment agreement fund | ÂĄ | ÂĄ 585,000 | ||||||||
Invested total amount | ÂĄ | 100,000 | ||||||||
RMB [Member] | Songlu Pharmaceutical [Member] | |||||||||
Financial Assets Available for Sale (Textual) | |||||||||
Invested total amount | ÂĄ | ÂĄ 600,000 |
Trade Accounts Receivable (Deta
Trade Accounts Receivable (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Receivables [Abstract] | ||
Accounts receivable | $ 11,939,364 | $ 12,883,707 |
Less: allowance for doubtful accounts | (3,246,850) | (4,561,314) |
Trade accounts receivable, net | $ 8,692,514 | $ 8,322,393 |
Trade Accounts Receivable (De_2
Trade Accounts Receivable (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Trade Accounts Receivable (Textual) | ||
Accounts receivable written off | $ 146,593 | $ 203,095 |
Other Current Assets (Details)
Other Current Assets (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Other Current Assets [Abstract] | |||
Prepaid rental expenses | [1] | $ 1,979,852 | $ 1,984,856 |
Prepaid and other current assets | 83,523 | 131,381 | |
Total | $ 2,063,375 | $ 2,116,237 | |
[1] | Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Property, Plant and Equipment [Line Items] | |||
Total | $ 23,183,960 | $ 17,255,788 | |
Less: Accumulated depreciation | (12,111,409) | (11,905,893) | |
Impairment | [1] | (2,345,193) | (2,506,255) |
Property and equipment, net | 8,727,358 | 2,843,640 | |
Building [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | [2] | 6,436,297 | 1,707,145 |
Leasehold improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 8,944,025 | 7,606,496 | |
Farmland development cost [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 1,781,627 | 1,904,151 | |
Office equipment and furniture [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 5,470,084 | 5,581,554 | |
Motor vehicles [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | $ 551,927 | $ 456,442 | |
[1] | The variance of impairment from March 31, 2019 to March 31, 2018 is solely caused by exchange rate variance. | ||
[2] | The increase in property and equipment from March 31, 2018 to December 31, 2018 is primarily due to the purchase of Yueming shop, a new building which cost $4,842,670 (RMB32,482,394). The new shop is located downtown south Hangzhou and adjacent to a super shopping mall. The Company plans to create a new flagship store. |
Property and Equipment (Detai_2
Property and Equipment (Details Textual) | 12 Months Ended | ||
Mar. 31, 2019USD ($) | Mar. 31, 2019CNY (ÂĄ) | Mar. 31, 2018USD ($) | |
Property and Equipment (Textual) | |||
Depreciation expenses for property and equipment | $ 1,221,520 | $ 1,268,282 | |
Purchase of new store | $ 4,722,193 | ||
RMB [Member] | |||
Property and Equipment (Textual) | |||
Purchase of new store | ÂĄ | ÂĄ 32,482,394 |
Advances to Suppliers (Details)
Advances to Suppliers (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Advances to Suppliers [Abstract] | |||
Advance to suppliers | [1] | $ 2,477,226 | $ 6,505,545 |
Less: allowance for doubtful accounts | [1] | (526,974) | (3,058,092) |
Advance to suppliers, net | $ 1,950,252 | $ 3,447,452 | |
[1] | In fiscal 2019, in order to use our cash more efficiently, Jiuxin Medicine accelerated the collection of advance to suppliers. Specifically, we focused on the collection of aged accounts of advances to suppliers. As we have collected these amounts, our allowance on doubtful accounts decreased. |
Inventory (Details)
Inventory (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Inventory (Textual) | ||
Finished goods | $ 13,955,202 | $ 13,429,568 |
Farmland Assets (Details)
Farmland Assets (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Farmland Assets [Abstract] | |||
Farmland assets | $ 2,341,537 | $ 2,416,839 | |
Less: Impairment | [1] | (1,516,278) | (1,620,554) |
Farmland assets, net | $ 825,259 | $ 796,286 | |
[1] | As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture's farmland, including their cultivation cost and land lease amortization expense, is approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees is approximately $796,286. As a result, the Company recorded an agricultural inventory impairment of $1,620,554. There are no leasehold impairment expense in fiscal 2019. |
Farmland Assets (Details Textua
Farmland Assets (Details Textual) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Farmland Assets (Textual) | |||
Book value | $ 2,341,537 | $ 2,416,839 | |
Book value approximately | 825,259 | 796,286 | |
Agricultural inventory impairment | [1] | $ 1,516,278 | $ 1,620,554 |
[1] | As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture's farmland, including their cultivation cost and land lease amortization expense, is approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees is approximately $796,286. As a result, the Company recorded an agricultural inventory impairment of $1,620,554. There are no leasehold impairment expense in fiscal 2019. |
Long Term Deposits, Landlords (
Long Term Deposits, Landlords (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Long Term Deposits, Landlords (Textual) | ||
Long term deposits | $ 2,157,275 | $ 2,501,968 |
Other Noncurrent Assets (Detail
Other Noncurrent Assets (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Other Assets, Noncurrent Disclosure [Abstract] | |||
Forest land use rights | [1] | $ 1,103,235 | $ 1,235,253 |
Others | 92,962 | 18,099 | |
Total | $ 1,196,197 | $ 1,253,352 | |
[1] | The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. |
Other Noncurrent Assets (Deta_2
Other Noncurrent Assets (Details 1) | Mar. 31, 2019USD ($) |
Other Assets, Noncurrent Disclosure [Abstract] | |
2020 | $ 28,071 |
2021 | 28,071 |
2022 | 28,071 |
2023 | 28,071 |
2024 | 28,071 |
Thereafter | $ 929,519 |
Other Noncurrent Assets (Deta_3
Other Noncurrent Assets (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Other Noncurrent Assets (Textual) | ||
Amortization of prepayment for lease of land use right | $ 28,071 | $ 28,377 |
Description of lease prepayment life | Extends the life of the lease to January 31, 2060. |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 | |
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | $ 4,038,754 | $ 4,284,660 | |
Less: accumulated amortization | (441,431) | (228,246) | |
Intangible assets, net | 3,597,323 | 4,056,414 | |
License [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | [1] | 1,909,700 | 1,967,934 |
SAP software [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | 676,336 | 764,104 | |
Land use rights [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | [2] | $ 1,452,718 | $ 1,552,622 |
[1] | This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores' business and liquidate all of the stores' accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time. | ||
[2] | In July 2013, the Company purchased the land use rights of a plot of land in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future. |
Intangible Assets (Details Text
Intangible Assets (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Intangible Assets (Textual) | ||
Amortization expense of intangibles | $ 228,046 | $ 115,528 |
Notes Payable (Details)
Notes Payable (Details) - USD ($) | 12 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | ||
Short-term Debt [Line Items] | |||
Notes payable | $ 25,951,673 | $ 19,180,200 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/10/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Apr. 10, 2018 | |
Notes payable | [1] | 2,522,769 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/24/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | May 24, 2018 | |
Notes payable | [1] | 21,972 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 5, 2018 | |
Notes payable | [1] | 377,347 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 29, 2018 | |
Notes payable | [1] | 1,194,135 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 29, 2018 | |
Notes payable | [1] | 1,443,554 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 02/05/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Aug. 5, 2018 | |
Notes payable | [1] | 2,618,500 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/05/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Sep. 5, 2018 | |
Notes payable | [1] | 3,072,637 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/06/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [2] | May 6, 2018 | |
Notes payable | [1] | 3,553,014 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Aug. 6, 2017 | |
Notes payable | [1] | 1,937,683 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 29, 2018 | |
Notes payable | [1] | 1,687,711 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/06/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | May 6, 2019 | |
Notes payable | [1] | $ 500,857 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/12/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 12, 2019 | |
Notes payable | [1] | $ 2,236,559 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/20/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 20, 2019 | |
Notes payable | [1] | $ 1,072,606 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Jun. 29, 2019 | |
Notes payable | [1] | $ 5,504,943 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 02/14/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Aug. 14, 2019 | |
Notes payable | [1] | $ 2,587,331 | |
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/06/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Sep. 6, 2019 | |
Notes payable | [1] | $ 6,600,727 | |
Jiuxin Medicine [Member] | HUB [Member] | 11/06/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | Apr. 11, 2019 | |
Notes payable | [1] | $ 2,987,119 | |
Jiuxin Medicine [Member] | HUB [Member] | 10/11/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [1] | May 6, 2019 | |
Notes payable | [1] | $ 4,461,531 | |
Jiuxin Medicine [Member] | CMB [Member] | 02/02/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [2] | Aug. 2, 2018 | |
Notes payable | [2] | 71,648 | |
Jiuxin Medicine [Member] | CMB [Member] | 02/07/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [2] | Aug. 7, 2018 | |
Notes payable | [2] | $ 95,531 | |
Jiuxin Medicine [Member] | CMB [Member] | 03/07/18 [Member | |||
Short-term Debt [Line Items] | |||
Maturity date | [2] | Sep. 7, 2018 | |
Notes payable | [2] | $ 538,857 | |
Jiuxin Medicine [Member] | CMB [Member] | 03/15/18 [Member] | |||
Short-term Debt [Line Items] | |||
Maturity date | [2] | Sep. 15, 2018 | |
Notes payable | [2] | $ 44,842 | |
[1] | As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2019, the Company had $25,951,673 (RMB 174,203,868) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $15,114,740 (RMB 101,459,590) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,446,381 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. | ||
[2] | As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank. |
Notes Payable (Details Textual)
Notes Payable (Details Textual) | 12 Months Ended | |||
Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Mar. 31, 2019CNY (ÂĄ) | Mar. 31, 2018CNY (ÂĄ) | |
Notes Payable (Textual) | ||||
Notes payable | $ 25,950,000 | |||
Line of credit total | 28,380,000 | |||
Bank credit line facilities available for borrowing | 2,430,000 | |||
HUB [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | 10,450,000 | |||
Restricted cash | 4,670,000 | |||
Line of credit total | 13,260,000 | |||
HUB [Member] | Notes Payable to Banks [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | 25,951,673 | $ 18,429,322 | ||
Restricted cash | 15,114,740 | 13,565,300 | ||
HUB [Member] | Notes Payable to Banks [Member] | RMB [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | ÂĄ | ÂĄ 174,203,868 | ÂĄ 115,748,985 | ||
Restricted cash | ÂĄ | 101,459,590 | 85,199,540 | ||
HUB One [Member] | Notes Payable to Banks [Member] | ||||
Notes Payable (Textual) | ||||
Restricted cash | $ 10,446,381 | $ 7,269,509 | ||
Term of deposit | 3 years | 3 years | ||
HUB One [Member] | Notes Payable to Banks [Member] | RMB [Member] | ||||
Notes Payable (Textual) | ||||
Restricted cash | ÂĄ | ÂĄ 70,122,647 | 45,657,584 | ||
CMB [Member] | Notes Payable to Banks [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | $ 750,878 | |||
Restricted cash | $ 750,878 | |||
CMB [Member] | Notes Payable to Banks [Member] | RMB [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | ÂĄ | 4,716,037 | |||
Restricted cash | ÂĄ | ÂĄ 4,716,037 |
Taxes (Details)
Taxes (Details) | 12 Months Ended |
Mar. 31, 2019 | |
Renovation [Member] | |
Income Taxes [Line Items] | |
Income Tax Jurisdiction | Hong Kong, PRC |
All other entities [Member] | |
Income Taxes [Line Items] | |
Income Tax Jurisdiction | Mainland, PRC |
Jo-Jo Drugstores [Member] | |
Income Taxes [Line Items] | |
Income Tax Jurisdiction | United States |
Taxes (Details 1)
Taxes (Details 1) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Current: | ||
Federal | ||
State | ||
Foreign | 134,763 | 76,256 |
Total | 134,763 | 76,256 |
Deferred: | ||
Federal | ||
State | ||
Foreign | ||
Total | ||
Provision for income taxes | $ 134,763 | $ 76,256 |
Taxes (Details 2)
Taxes (Details 2) | 12 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | ||
Income Tax Disclosure [Abstract] | |||
U.S. Statutory rates | 21.00% | 21.00% | |
Foreign income not recognized in the U.S. | (21.00%) | (21.00%) | |
China income taxes | 25.00% | 25.00% | |
Change in valuation allowance | [1] | (25.00%) | (25.00%) |
Non-deductible expenses-permanent difference | [2] | (11.40%) | (0.40%) |
Effective tax rate | (11.40%) | (0.40%) | |
[1] | Represents a non-taxable expense reversal due to overall decrease in allowance for accounts receivable and advances to suppliers. | ||
[2] | The (11.4)% and (0.4)% rate adjustments for the years ended March 31, 2019 and 2018 represent expenses that primarily include stock option expenses and other expenses incurred by the Company that are not deductible for PRC income tax. |
Taxes (Details 3)
Taxes (Details 3) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Income Tax Disclosure [Abstract] | ||
Allowance | $ 986,665 | $ 1,214,946 |
Long-lived assets impairment | 586,298 | 395,797 |
Depreciation and Amortization | 345,952 | |
Accrued expense | 1,569,683 | 245,056 |
Net operating loss carryforward | 1,164,735 | 654,282 |
Foreign Tax Credit Carryover | 195,000 | 195,000 |
Total deferred tax assets (liabilities): | 4,502,381 | 3,051,033 |
Valuation allowance | (4,502,381) | (3,051,033) |
Net deferred tax assets (liabilities) |
Taxes (Details Textual)
Taxes (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Dec. 22, 2017 | Mar. 31, 2019 | Mar. 31, 2018 | Jan. 31, 2019 | Mar. 31, 2017 | |
Taxes (Textual) | |||||
Estimated net operating loss carry forwards for U.S. income tax purposes | $ 1,164,735 | $ 654,282 | |||
Effective tax rate | (11.40%) | (0.40%) | |||
Foreign tax credit | $ 195,000 | ||||
Income tax, description | The U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. ASC 740 requires companies to recognize the effect of tax law changes in the period of enactment, accordingly, the effects must be recognized on companies' calendar year-end financial statements, even though the effective date for most provisions is January 1, 2018. As a result, we re-measured our net U.S. deferred tax assets at the 21% future tax rate. | Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years as the Company's most significant tax jurisdiction. | |||
Net unrecognized tax benefits | $ 0 | ||||
Percentage of corporate tax rate | 21.00% | ||||
Hong Kong Income Tax [Member] | |||||
Taxes (Textual) | |||||
Estimated net operating loss carry forwards for U.S. income tax purposes | $ 1,960,933 | $ 1,882,276 | |||
Us Income Tax [Member] | |||||
Taxes (Textual) | |||||
Estimated net operating loss carry forwards for U.S. income tax purposes | $ 816,908 | 816,908 | |||
Expiration date | Mar. 31, 2032 | ||||
China Income Tax [Member] | |||||
Taxes (Textual) | |||||
Estimated net operating loss carry forwards for U.S. income tax purposes | $ 2,678,523 | $ 688,622 |
Postretirement Benefits (Detail
Postretirement Benefits (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Postretirement Benefits (Textual) | ||
Employment benefits and pension contribution | $ 1,423,449 | $ 1,257,362 |
Related Party Transactions an_3
Related Party Transactions and Arrangements (Details) - USD ($) | Mar. 31, 2019 | Mar. 31, 2018 |
Due to a director and CEO [Member] | ||
Related Party Transaction [Line Items] | ||
Total | $ 795,179 | $ 850,342 |
Related Party Transactions an_4
Related Party Transactions and Arrangements (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |
Apr. 28, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Related Party Transactions and Arrangements (Textual) | |||
Notes payable, related parties | $ 0 | $ 3,253,630 | |
Chief Executive Officer [Member] | |||
Related Party Transactions and Arrangements (Textual) | |||
Lease expiration date | Sep. 30, 2020 | ||
Rent expenses | $ 27,605 | $ 18,120 | |
Ownership percentage | 51.00% | ||
Hangzhou Kangzhou Biotech Co. Ltd. [Member] | |||
Related Party Transactions and Arrangements (Textual) | |||
Total proceeds | $ 75,643 | ||
Sale of percentage | 10.00% | ||
Hangzhou Kangzhou Biotech Co. Ltd. [Member] | RMB [Member] | |||
Related Party Transactions and Arrangements (Textual) | |||
Total proceeds | $ 507,760 |
Warrants (Details)
Warrants (Details) - Warrant [Member] - $ / shares | 12 Months Ended | ||
Mar. 31, 2019 | [1] | Mar. 31, 2018 | |
Class of Warrant or Right [Line Items] | |||
Stock price | $ 2.62 | $ 1.35 | |
Exercise price | $ 3.10 | $ 3.10 | |
Annual dividend yield | 0.00% | 0.00% | |
Expected term (years) | 1 year 9 months 18 days | 2 years 9 months 18 days | |
Risk-free interest rate | 2.27% | 1.98% | |
Expected volatility | 67.69% | 68.73% | |
[1] | As of March 31, 2019, the warrants had not been exercised. |
Warrants (Details Textual)
Warrants (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |
Jul. 19, 2015 | Mar. 31, 2019 | Mar. 31, 2018 | |
Warrants (Textual) | |||
Fair value estimation method | Binominal pricing model | ||
Fair value of warrant liability | $ 138,796 | ||
Purchase of warrants investors | 672,000 | ||
Recognized gain on fair value of warrant liability investor placement agent | $ 32,645,200 | ||
Fair value of warrant liability investor placement agent | $ 46,524,800 | ||
Warrant [Member] | |||
Warrants (Textual) | |||
Stock purchase price per share (in dollars per share) | $ 3.10 | ||
Warrants exercisable date | Jan. 19, 2016 | ||
Maturity date | Jan. 18, 2021 | ||
Purchase of warrants investors | 600,000 | ||
Issuance of warrants to placement agent | 72,000 | ||
Percentage of stock sold in offering | 6.00% |
Financial Liability (Details)
Financial Liability (Details) - Mar. 31, 2019 | USD ($) | CNY (ÂĄ) |
Financial Liability (Textual) | ||
Reclassifies deposits financial liability | $ | $ 81,935 | |
RMB [Member] | ||
Financial Liability (Textual) | ||
Reclassifies deposits financial liability | ÂĄ | ÂĄ 550,000 |
Stockholder's Equity (Details)
Stockholder's Equity (Details) | Nov. 18, 2014Segment$ / sharesshares | Apr. 15, 2019USD ($)$ / sharesshares | Jun. 28, 2018shares | Mar. 30, 2018shares | Jan. 23, 2017USD ($)$ / sharesshares | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) |
Stockholder's Equity (Textual) | |||||||
Reserve fund percentage | 50.00% | ||||||
Statutory accounts percentage | 10.00% | ||||||
Compensation committee cancelled shares | 225,000 | ||||||
Chief Executive Officer [Member] | |||||||
Stockholder's Equity (Textual) | |||||||
Aggregate issuances shares | 675,000 | ||||||
Performance based compensation exemption, description | The Tax Cuts and Jobs Act of 2017 removed the 162(m) qualified performance based compensation exemption to the $1 million cap on deductions for compensation to covered executives. | ||||||
Employee Stock Option [Member] | |||||||
Stockholder's Equity (Textual) | |||||||
Number of granted shares | 967,000 | ||||||
Share based compensation expense | $ | $ 0 | ||||||
Number of directors, officers and employees in a group | Segment | 46 | ||||||
Exercise price of stock option | $ / shares | $ 2.50 | ||||||
Period for options exercisable from the vesting date | 5 years | ||||||
Maturity date | Nov. 17, 2022 | ||||||
Common Stock [Member] | |||||||
Stockholder's Equity (Textual) | |||||||
Company sold common stock to investor | 4,840,000 | ||||||
Common stock, par value | $ / shares | $ 0.001 | ||||||
Purchase price | $ / shares | $ 2.20 | ||||||
Proceeds from private placement | $ | $ 10,648,000 | ||||||
Common Stock [Member] | Subsequent Event [Member] | |||||||
Stockholder's Equity (Textual) | |||||||
Company sold common stock to investor | 4,000,008 | ||||||
Common stock, par value | $ / shares | $ 2.50 | ||||||
Proceeds from private placement | $ | $ 10,000,020 | ||||||
Stock Compensation Plan Three [Member] | |||||||
Stockholder's Equity (Textual) | |||||||
Number of granted shares | 3,947,100 | ||||||
Share based compensation expense | $ | $ 5,328,585 |
Loss Per Share (Details)
Loss Per Share (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
LOSS PER SHARES: | ||
Net income attributable to controlling interest | $ (1,317,769) | $ (17,059,933) |
Weighted average shares used in basic computation | 28,936,778 | 25,241,748 |
Diluted effect of stock options and warrants | ||
Weighted average shares used in diluted computation | 28,936,778 | 25,241,748 |
Income per share - Basic: | ||
Net income before noncontrolling interest | $ (0.03) | $ (0.68) |
Add: Net loss attributable to noncontrolling interest | ||
Net income before noncontrolling interest | (0.03) | (0.68) |
Loss per share - Diluted: | ||
Net income before noncontrolling interest | (0.03) | (0.68) |
Add: Net income attributable to noncontrolling interest | ||
Diluted | $ (0.03) | $ (0.68) |
Loss Per Share (Details Textual
Loss Per Share (Details Textual) - Employee Stock Option [Member] | 12 Months Ended |
Mar. 31, 2019shares | |
Loss Per Share (Textual) | |
Antidilutive securities excluded from calculation of diluted earnings per share | 967,000 |
Private Placement [Member] | |
Loss Per Share (Textual) | |
Antidilutive securities excluded from calculation of diluted earnings per share | 72,000 |
Investor [Member] | |
Loss Per Share (Textual) | |
Antidilutive securities excluded from calculation of diluted earnings per share | 600,000 |
Segments (Details)
Segments (Details) - USD ($) | 12 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | |||
Segment Reporting Information [Line Items] | ||||
Revenue | $ 107,551,012 | $ 96,112,706 | ||
Cost of goods | 82,442,969 | 75,987,537 | ||
Gross profit | 25,108,043 | 20,125,169 | ||
Selling expenses | 24,265,184 | 18,739,492 | ||
General and administrative expenses | 1,718,989 | [1] | 17,823,661 | [2] |
Impairment of long-lived assets | 1,583,186 | |||
Loss from operations | (876,130) | (18,021,170) | ||
Depreciation and amortization | 1,484,547 | 1,215,107 | ||
Total capital expenditures | 7,269,281 | 889,036 | ||
Retail drugstores [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 72,334,409 | 61,977,582 | ||
Cost of goods | 51,246,983 | 45,918,540 | ||
Gross profit | 21,087,426 | 16,059,042 | ||
Selling expenses | 18,930,118 | 13,037,239 | ||
General and administrative expenses | 4,072,500 | 14,730,152 | ||
Impairment of long-lived assets | ||||
Loss from operations | (1,915,192) | (11,708,349) | ||
Depreciation and amortization | 1,476,903 | 837,195 | ||
Total capital expenditures | 7,267,847 | 878,121 | ||
Online Pharmacy [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 8,784,459 | 12,132,930 | ||
Cost of goods | 7,748,519 | 10,858,160 | ||
Gross profit | 1,035,940 | 1,274,770 | ||
Selling expenses | 1,735,966 | 2,014,414 | ||
General and administrative expenses | 347,516 | 427,772 | ||
Impairment of long-lived assets | ||||
Loss from operations | (1,047,542) | (1,167,416) | ||
Depreciation and amortization | ||||
Total capital expenditures | ||||
Drug Wholesale [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 26,432,144 | 22,002,194 | ||
Cost of goods | 23,447,467 | 19,210,837 | ||
Gross profit | 2,984,677 | 2,791,357 | ||
Selling expenses | 3,599,100 | 3,687,839 | ||
General and administrative expenses | (2,701,027) | 2,630,278 | ||
Impairment of long-lived assets | 1,583,186 | |||
Loss from operations | 2,086,604 | (5,109,946) | ||
Depreciation and amortization | 7,644 | 377,912 | ||
Total capital expenditures | 1,434 | 10,915 | ||
Herb farming [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | ||||
Cost of goods | ||||
Gross profit | ||||
Selling expenses | ||||
General and administrative expenses | 35,459 | |||
Impairment of long-lived assets | ||||
Loss from operations | (35,459) | |||
Depreciation and amortization | ||||
Total capital expenditures | ||||
[1] | Includes additional accounts receivable and advance to suppliers allowance of $(3,845,582) | |||
[2] | Includes additional accounts receivable and advance to suppliers allowance of $4,701,647 |
Segments (Details 1)
Segments (Details 1) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | $ 107,551,012 | $ 96,112,706 |
Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 26,432,144 | 22,002,194 |
Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 8,784,459 | 12,132,930 |
Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 72,334,409 | 61,977,582 |
Herbs Farming [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | ||
Prescription Drugs [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 16,745,862 | 12,314,829 |
Prescription Drugs [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | ||
Prescription Drugs [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 23,516,046 | 20,553,179 |
OTC drugs [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 8,964,587 | 9,381,932 |
OTC drugs [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 3,127,976 | 5,193,051 |
OTC drugs [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 31,401,328 | 28,368,059 |
Nutritional Supplements [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 290,534 | 182,903 |
Nutritional Supplements [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 737,315 | 29,717 |
Nutritional Supplements [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 6,354,108 | 4,179,139 |
TCM [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 271,280 | 73,645 |
TCM [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 74,262 | 3,932,607 |
TCM [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 6,529,790 | 1,660,301 |
Sundry Products [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 24,846 | 48,852 |
Sundry Products [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 2,736,070 | 1,880,707 |
Sundry Products [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 941,491 | 6,254,286 |
Medical Devices [Member] | Drug Wholesale [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 135,035 | 32 |
Medical Devices [Member] | Online pharmacy [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | 2,108,836 | 1,096,849 |
Medical Devices [Member] | Retail drugstores [Member] | ||
Revenue from External Customer [Line Items] | ||
Net revenue from external customers | $ 3,591,646 | $ 962,619 |
Segments (Details Textual)
Segments (Details Textual) | 12 Months Ended |
Mar. 31, 2019Segment | |
Segments (Textual) | |
Number of operating segments | 4 |
Commitments and Contingencies_2
Commitments and Contingencies (Details) | Mar. 31, 2019USD ($) |
Commitments and Contingencies [Line Items] | |
2020 | $ 4,952,693 |
2021 | 4,041,356 |
2022 | 3,236,573 |
2023 | 2,317,018 |
2024 | 1,735,252 |
Thereafter | 2,039,618 |
Retail drugstores [Member] | |
Commitments and Contingencies [Line Items] | |
2020 | 4,952,693 |
2021 | 4,041,356 |
2022 | 3,236,573 |
2023 | 2,317,018 |
2024 | 1,735,252 |
Thereafter | 2,039,618 |
Drug wholesale [Member] | |
Commitments and Contingencies [Line Items] | |
2020 | |
2021 | |
2022 | |
2023 | |
2024 | |
Thereafter | |
Online pharmacy [Member] | |
Commitments and Contingencies [Line Items] | |
2020 | |
2021 | |
2022 | |
2023 | |
2024 | |
Thereafter | |
Herb farming [Member] | |
Commitments and Contingencies [Line Items] | |
2020 | |
2021 | |
2022 | |
2023 | |
2024 | |
Thereafter |
Commitments and Contingencies_3
Commitments and Contingencies (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Commitments and Contingencies (Textual) | ||
Total rent expenses | $ 4,744,200 | $ 4,160,748 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) | 1 Months Ended | |
Apr. 15, 2019 | Jan. 23, 2017 | |
Common Stock [Member] | ||
Exercise price | $ 2.20 | |
Sales of common stock shares offering | 4,840,000 | |
Common stock, par value | $ 0.001 | |
Proceeds from private placement | $ 10,648,000 | |
Subsequent Event [Member] | Common Stock [Member] | ||
Sales of common stock shares offering | 4,000,008 | |
Common stock, par value | $ 2.50 | |
Proceeds from private placement | $ 10,000,020 | |
Subsequent Event [Member] | Warrant [Member] | ||
Aggregate of common stock, shares | 3,000,006 | |
Exercise price | $ 3 | |
Warrant exercise price | $ 3.125 | |
Percentage shares of common stock | 6.00% | |
Sales of common stock shares offering | 240,000 | |
Warrants expiry date | Apr. 11, 2024 |